Represent

Lobbying
Lobbying by Elevance Health, Inc.

Lobbying Relationship

Client

Elevance Health, Inc.

More records

Lobbying firm

Elevance Health, Inc.

More records

Prior Authorization Mental Health and Substance Use Behavioral Health Crisis Intervention 9-8-8 hotline services Mental Health Parity Facilitating Accountability in Reimbursements Act (FAIR Act) (H.R. 3417) Site-based Invoicing and Transparency Enhancement (SITE) Act (S.1869) Lower Cost, More Transparency Act (H.R. 5378) Primary Care and Workforce Act (S. 2840) AI Use in Healthcare Health Disparities, including Maternal Health and Rural Health H.R. 3520 Veteran Care Improvement Act of 2023. Making Community Care Work for Veterans Act of 2023 (S.2649) Dept. of Defense Military OneSource Program H.R. 2670 FY2024 National Defense Authorization Act of 2024 Provider Directories Transparency in Coverage and Machine-Readable Files Affordable Connectivity Program Change Healthcare Cyber Incident
Medicare Advantage Supplemental Benefits Local Coverage Determinations - Coverage Determination Clarity Act of 2023 (H.R. 5396) Puerto Rico Medicaid Program Funding - Federal Matching Assistance Percentage (FMAP) Fairness in Medicare Part B Enrollment Act of 2023 (H.R. 4027) Fairness in Medicare Savings Program Act of 2023 (H.R. 4410) Medicare Advantage Integrity Act of 2023 (H.R. 4411) Medicare Advantage & Medicare Part D Prescription Drug Program Territories Medicare Prescription Drug Assistance Equality Act of 2021 (H.R. 1825) Medicaid Managed Care Medicaid Eligibility and Redetermination Medicare Site Neutrality Medicare & Medicaid Social Determinants of Health (SDOH)
Biosimilar Red Tape Elimination Act (S. 2305) Drug Patent Reform Pharmacy Benefit Manager (PBM) operations and practices, Spread Pricing, Rebates, Delinking Protecting Patients Against PBM Abuses Act (H.R. 2880) Drug Act (H.R. 6283) Robinson-Patman Act Reform Modernizing and Ensuring PBM Accountability (MEPA) Act (S.2973) Pharmacy Benefit Manager Transparency Act (S. 127) Pharmacy Benefit Manager Reform Act (S. 1339) Patients Before Middlemen Act (S.1967) Biologics Competition Act (H.R. 1790) Drug-Price Transparency for Consumers Act (S. 1250) Lower Cost, More Transparency Act (H.R. 5378) NADAC Reporting

Duration: January 9, 2006 to present

General Issues: Health Issues, Insurance, Medicare/Medicaid, Pharmacy, Financial Institutions/Investments/Securities, Taxation/Internal Revenue Code, Consumer Issues/Safety/Protection, Labor Issues/Antitrust/Workplace, Veterans, Budget/Appropriations, Medical/Disease Research/Clinical Labs, Banking

Spending: about $87,970,000 (But it's complicated. Here's why.)

Agencies lobbied since 2006: U.S. Senate, House of Representatives, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), White House Office, Defense - Dept of (DOD), Treasury - Dept of, Labor - Dept of (DOL), U.S. Postal Service (USPS), Agency for Healthcare Research & Quality (AHRQ), Health & Human Services - Dept of (HHS), Natl Economic Council (NEC), Federal Reserve System, Justice - Dept of (DOJ), Office of Management & Budget (OMB), Federal Communications Commission (FCC), Substance Abuse & Mental Health Services Administration (SAMHSA), Medicare Payment Advisory Commission (MedPAC), Federal Trade Commission (FTC), Congressional Budget Office (CBO), Treasury - Dept of,, Transportation - Dept of (DOT), Commerce - Dept of (DOC), Centers For Medicare and Medicaid Services (CMS),, U.S. Senate,

Bills mentioned

H.R.1628: American Health Care Act of 2017

Sponsor: Diane Black (R-Tenn.)

H.RES.154: Of inquiry requesting the President of the United States and directing...

Sponsor: Joseph P. Kennedy III (D-Mass.)

S.1201: Health Care Options for All Act

Sponsor: Claire McCaskill (D-Mo.)

S.1354: Individual Health Insurance Marketplace Improvement Act

Sponsor: Thomas R. Carper (D-Del.)

S.1462: Marketplace Certainty Act

Sponsor: Jeanne Shaheen (D-N.H.)

H.R.3545: Overdose Prevention and Patient Safety Act

Sponsor: Tim Murphy (R-Pa.)

H.R.3168: SNP Reauthorization Act of 2017

Sponsor: Pat Tiberi (R-Ohio)

S.870: Creating High-Quality Results and Outcomes Necessary to Improve Chronic...

Sponsor: Orrin G. Hatch (R-Utah)

H.R.2556: CONNECT for Health Act of 2017

Sponsor: Diane Black (R-Tenn.)

S.1016: CONNECT for Health Act of 2017

Sponsor: Brian Schatz (D-Hawaii)

H.R.3727: ITAM Act

Sponsor: Diane Black (R-Tenn.)

S.1827: KIDS Act of 2017

Sponsor: Orrin G. Hatch (R-Utah)

S.1519: National Defense Authorization Act for Fiscal Year 2018

Sponsor: John McCain (R-Ariz.)

H.R.246: To repeal the annual fee on health insurance providers enacted by the...

Sponsor: Kristi Noem (R-S.D.)

H.R.372: Competitive Health Insurance Reform Act of 2017

Sponsor: Paul Gosar (R-Ariz.)

H.R.1101: Small Business Health Fairness Act of 2017

Sponsor: Sam Johnson (R-Texas)

H.R.1215: Protecting Access to Care Act of 2017

Sponsor: Steve King (R-Iowa)

H.R.1304: Self-Insurance Protection Act

Sponsor: Phil Roe (R-Tenn.)

H.R.1121: Pre-existing Conditions Protection Act of 2017

Sponsor: Greg Walden (R-Ore.)

H.R.633: Patient Fairness and Relief Act of 2017

Sponsor: Gregg Harper (R-Miss.)

H.R.661: Employee Fairness and Relief Act of 2017

Sponsor: Brett Guthrie (R-Ky.)

H.R.706: Plan Verification and Fairness Act of 2017

Sponsor: Marsha Blackburn (R-Tenn.)

H.R.708: State Age Rating Flexibility Act of 2017

Sponsor: Larry Bucshon (R-Ind.)

H.R.710: Health Coverage State Flexibility Act of 2017

Sponsor: Bill Flores (R-Texas)

H.R.749: Lower Drug Costs through Competition Act

Sponsor: Kurt Schrader (D-Ore.)

S.544: A bill to amend the Veterans Access, Choice, and Accountability Act of...

Sponsor: Jon Tester (D-Mont.)

H.R.369: To eliminate the sunset of the Veterans Choice Program, and for other...

Sponsor: Phil Roe (R-Tenn.)

S.2803: Taxpayers Before Insurers Act

Sponsor: Ben Sasse (R-Neb.)

H.R.5904: Taxpayers Before Insurers Act

Sponsor: Mark Walker (R-N.C.)

H.R.5921: State Age Rating Flexibility Act of 2016

Sponsor: Larry Bucshon (R-Ind.)

H.R.5589: Plan Verification and Fairness Act of 2016

Sponsor: Marsha Blackburn (R-Tenn.)

H.R.3742: Access to Marketplace Insurance Act

Sponsor: Kevin Cramer (R-N.D.)

H.R.5410: Health Coverage State Flexibility Act of 2016

Sponsor: Bill Flores (R-Texas)

H.R.5447: Small Business Health Care Relief Act of 2016

Sponsor: Charles Boustany Jr. (R-La.)

S.2484: CONNECT for Health Act

Sponsor: Brian Schatz (D-Hawaii)

H.R.4442: CONNECT for Health Act

Sponsor: Diane Black (R-Tenn.)

S.2943: National Defense Authorization Act for Fiscal Year 2017

Sponsor: John McCain (R-Ariz.)

H.R.5659: ESRD Choice Act of 2016

Sponsor: Jason Smith (R-Mo.)

S.3504: Creating High-Quality Results and Outcomes Necessary to Improve Chronic...

Sponsor: Orrin G. Hatch (R-Utah)

H.R.6226: PUSH Act of 2016

Sponsor: Tom Price (R-Ga.)

S.183: Jobs and Premium Protection Act

Sponsor: John Barrasso (R-Wyo.)

H.R.928: To repeal the annual fee on health insurance providers enacted by the...

Sponsor: Charles Boustany Jr. (R-La.)

H.R.2646: Helping Families in Mental Health Crisis Act of 2016

Sponsor: Tim Murphy (R-Pa.)

H.R.4276: Behavioral Health Coverage Transparency Act of 2015

Sponsor: Joseph P. Kennedy III (D-Mass.)

H.R.953: Comprehensive Addiction and Recovery Act of 2015

Sponsor: F. James Sensenbrenner (R-Wis.)

H.R.4909: National Defense Authorization Act for Fiscal Year 2017

Sponsor: William M. Thornberry (R-Texas)

H.R.546: ACE Kids Act of 2015

Sponsor: Joe L. Barton (R-Texas)

S.2045: Middle Class Health Benefits Tax Repeal Act of 2015

Sponsor: Dean Heller (R-Nev.)

H.R.2050: Middle Class Health Benefits Tax Repeal Act of 2015

Sponsor: Joe Courtney (D-Conn.)

H.R.879: Ax the Tax on Middle Class Americans' Health Plans Act

Sponsor: Frank Guinta (R-N.H.)

H.R.3323: DOC Access Act

Sponsor: Buddy Carter (R-Ga.)

S.1945: Mental Health Reform Act of 2015

Sponsor: Bill Cassidy (R-La.)

S.524: Comprehensive Addiction and Recovery Act of 2016

Sponsor: Sheldon Whitehouse (D-R.I.)

S.298: ACE Kids Act of 2015

Sponsor: Charles E. Grassley (R-Iowa)

S.2921: Veterans First Act

Sponsor: Johnny Isakson (R-Ga.)

S.2896: Care Veterans Deserve Act of 2016

Sponsor: John McCain (R-Ariz.)

H.R.5286: VA Construction and Lease Authorization, Health, and Benefits...

Sponsor: Jeff Miller (R-Fla.)

S.2343: Telehealth Innovation and Improvement Act of 2015

Sponsor: Cory Gardner (R-Colo.)

H.R.2029: Consolidated Appropriations Act, 2016

Sponsor: Charlie Dent (R-Pa.)

S.2633: Improving Veterans Access to Care in the Community Act

Sponsor: Jon Tester (D-Mont.)

S.2646: Veterans Choice Improvement Act of 2016

Sponsor: Richard M. Burr (R-N.C.)

H.R.4591: Department of Veterans Affairs Purchased Health Care Streamlining and...

Sponsor: Jeff Miller (R-Fla.)

S.1099: PACE Act

Sponsor: Tim Scott (R-S.C.)

H.R.1624: Protecting Affordable Coverage for Employees Act

Sponsor: Brett Guthrie (R-Ky.)

H.R.2396: SOFTWARE Act

Sponsor: Marsha Blackburn (R-Tenn.)

S.1101: MEDTECH Act

Sponsor: Michael Bennet (D-Colo.)

H.R.1021: Protecting the Integrity of Medicare Act of 2015

Sponsor: Kevin Brady (R-Texas)

H.R.2298: Medicare Patient Safety and Drug Abuse Prevention Act

Sponsor: Gus Bilirakis (R-Fla.)

S.1431: Prescription Drug Abuse Prevention and Treatment Act of 2015

Sponsor: Joe Manchin III (D-W.Va.)

H.R.2: Medicare Access and CHIP Reauthorization Act of 2015

Sponsor: Michael C. Burgess (R-Texas)

S.754: To improve cybersecurity in the United States through enhanced sharing...

Sponsor: Richard M. Burr (R-N.C.)

H.R.6: 21st Century Cures Act

Sponsor: Fred Upton (R-Mich.)

H.R.289: Better Efficiency and Administrative Simplification Act of 2015

Sponsor: Jim Renacci (R-Ohio)

H.R.3367: To amend section 9010 of the Patient Protection and Affordable Care Act...

Sponsor: Charles Boustany Jr. (R-La.)

H.R.763: To repeal the annual fee on health insurance providers enacted by the...

Sponsor: Charles Boustany Jr. (R-La.)

S.603: Jobs and Premium Protection Act

Sponsor: John Barrasso (R-Wyo.)

S.2214: Obamacare Taxpayer Bailout Protection Act

Sponsor: Marco Rubio (R-Fla.)

H.R.3489: To amend section 1341 of the Patient Protection and Affordable Care Act...

Sponsor: Pat Tiberi (R-Ohio)

H.R.3541: Obamacare Taxpayer Bailout Prevention Act

Sponsor: Tim Griffin (R-Ark.)

H.R.3812: No Bailouts for Insurance Industry Act of 2014

Sponsor: Mike Coffman (R-Colo.)

H.R.3750: Telehealth Modernization Act of 2013

Sponsor: Doris Matsui (D-Calif.)

H.R.3077: TELE-MED Act of 2013

Sponsor: Devin Nunes (R-Calif.)

S.1787: Medicaid Managed Care Responsibility and Equity Act

Sponsor: John D. Rockefeller IV (D-W.Va.)

H.R.3306: Telehealth Enhancement Act of 2013

Sponsor: Gregg Harper (R-Miss.)

H.R.4418: Expanding the Availability of Medicare Data Act

Sponsor: Paul D. Ryan (R-Wis.)

S.1758: Quality Data, Quality Healthcare Act of 2013

Sponsor: Tammy Baldwin (D-Wis.)

H.R.4302: Protecting Access to Medicare Act of 2014

Sponsor: Joe Pitts (R-Pa.)

H.R.4414: Expatriate Health Coverage Clarification Act of 2014

Sponsor: John Carney (D-Del.)

H.R.1946: Preserving Our Hometown Independent Pharmacies Act of 2011

Sponsor: Tom Marino (R-Pa.)

H.R.1971: Pharmacy Competition and Consumer Choice Act of 2011

Sponsor: Cathy McMorris Rodgers (R-Wash.)

H.R.3590: Patient Protection and Affordable Care Act

Sponsor: Charles B. Rangel (D-N.Y.)

H.R.3962: Preservation of Access to Care for Medicare Beneficiaries and Pension...

Sponsor: John D. Dingell (D-Mich.)

H.R.4872: Health Care and Education Reconciliation Act of 2010

Sponsor: John M. Spratt Jr. (D-S.C.)

S.1796: America's Healthy Future Act of 2009

Sponsor: Max Baucus (D-Mont.)

H.R.3200: America's Affordable Health Choices Act of 2009

Sponsor: John D. Dingell (D-Mich.)

S.CON.RES.13: An original concurrent resolution setting forth the congressional budget...

Sponsor: Kent Conrad (D-N.D.)

H.CON.RES.85: Setting forth the congressional budget for the United States Government...

Sponsor: John M. Spratt Jr. (D-S.C.)

H.R.1: American Recovery and Reinvestment Act of 2009

Sponsor: David R. Obey (D-Wis.)

S.275: Children's Health Insurance Program Reauthorization Act of 2009

Sponsor: Max Baucus (D-Mont.)

H.R.2: Children's Health Insurance Program Reauthorization Act of 2009

Sponsor: Frank Pallone (D-N.J.)

S.276: Social Security and Medicare Solvency Commission Act

Sponsor: Dianne Feinstein (D-Calif.)

H.R.1427: Promoting Innovation and Access to Life-Saving Medicine Act

Sponsor: Henry A. Waxman (D-Calif.)

S.334: Healthy Americans Act

Sponsor: Ron Wyden (D-Ore.)

H.R.3163: Healthy Americans Act

Sponsor: Brian Baird (D-Wash.)

S.1693: Wired for Health Care Quality Act

Sponsor: Edward M. Kennedy (D-Mass.)

H.R.2406: Healthcare Information Technology Enterprise Integration Act

Sponsor: Bart Gordon (D-Tenn.)

S.358: Genetic Information Nondiscrimination Act of 2007

Sponsor: Olympia J. Snowe (R-Maine)

H.R.493: Genetic Information Nondiscrimination Act of 2008

Sponsor: Louise M. Slaughter (D-N.Y.)

S.558: Mental Health Parity Act of 2007

Sponsor: Pete V. Domenici (R-N.M.)

H.R.1424: A bill to provide authority for the Federal Government to purchase and...

Sponsor: Patrick J. Kennedy (D-R.I.)

S.1019: Universal Health Care Choice and Access Act

Sponsor: Tom Coburn (R-Okla.)

H.R.6331: Medicare Improvements for Patients and Providers Act of 2008

Sponsor: Charles B. Rangel (D-N.Y.)

H.R.3162: Children's Health and Medicare Protection Act of 2007

Sponsor: John D. Dingell (D-Mich.)

S.CON.RES.70: An original concurrent resolution setting forth the congressional budget...

Sponsor: Kent Conrad (D-N.D.)

H.CON.RES.312: Revising the congressional budget for the United States Government for...

Sponsor: John M. Spratt Jr. (D-S.C.)

S.1835: Lower Premiums Through Reinsurance Act of 2017

Sponsor: Susan Collins (R-Maine)

S.191: Patient Freedom Act of 2017

Sponsor: Bill Cassidy (R-La.)

H.R.3922: CHAMPIONING HEALTHY KIDS Act

Sponsor: Greg Walden (R-Ore.)

H.R.3482: Evidence-Based Telehealth Expansion Act of 2017

Sponsor: Bill Johnson (R-Ohio)

S.520: Medicaid Accountability and Care Act of 2017

Sponsor: Bill Cassidy (R-La.)

H.R.3164: To amend title XVIII of the Social Security Act to expand access to home...

Sponsor: Diane Black (R-Tenn.)

S.1859: Healthcare Tax Relief Act

Sponsor: Cory Gardner (R-Colo.)

S.1978: Small Business and Family Health Tax Relief Act of 2017

Sponsor: Heidi Heitkamp (D-N.D.)

H.R.1: An Act to provide for reconciliation pursuant to titles II and V of the...

Sponsor: Kevin Brady (R-Texas)

H.R.1892: Bipartisan Budget Act of 2018

Sponsor: John B. Larson (D-Conn.)

S.1771: Departments of Labor, Health and Human Services, and Education, and...

Sponsor: Roy Blunt (R-Mo.)

S.974: Creating and Restoring Equal Access to Equivalent Samples Act of 2018

Sponsor: Patrick J. Leahy (D-Vt.)

H.R.2212: CREATES Act of 2017

Sponsor: Tom Marino (R-Pa.)

H.R.5009: Jessie's Law

Sponsor: Tim Walberg (R-Mich.)

S.778: Prescription Drug Monitoring Act of 2017

Sponsor: Amy Klobuchar (D-Minn.)

S.2456: CARA 2.0 Act of 2018

Sponsor: Rob Portman (R-Ohio)

H.R.1625: Consolidated Appropriations Act, 2018

Sponsor: Edward Royce (R-Calif.)

H.R.4579: Creating High-Quality Results and Outcomes Necessary to Improve Chronic...

Sponsor: Peter Welch (D-Vt.)

H.R.6082: Overdose Prevention and Patient Safety Act

Sponsor: Markwayne Mullin (R-Okla.)

H.R.6: SUPPORT for Patients and Communities Act

Sponsor: Greg Walden (R-Ore.)

H.R.5515: John S. McCain National Defense Authorization Act for Fiscal Year 2019

Sponsor: William M. Thornberry (R-Texas)

H.R.6042: To amend title XIX of the Social Security Act to delay the reduction in...

Sponsor: Brett Guthrie (R-Ky.)

H.R.5773: Preventing Addiction for Susceptible Seniors Act of 2018

Sponsor: Peter Roskam (R-Ill.)

H.R.5797: Individuals in Medicaid Deserve Care that is Appropriate and Responsible...

Sponsor: Mimi Walters (R-Calif.)

H.R.5963: To delay the reimposition of the annual fee on health insurance...

Sponsor: Kristi Noem (R-S.D.)

S.3063: Health Insurance Tax Relief Act of 2018

Sponsor: John Barrasso (R-Wyo.)

H.R.302: FAA Reauthorization Act of 2018

Sponsor: Brett Guthrie (R-Ky.)

H.R.3325: ACE Kids Act

Sponsor: Joe L. Barton (R-Texas)

S.3231: Task Force on the Impact of the Affordable Housing Crisis Act of 2018

Sponsor: Todd Young (R-Ind.)

S.3679: READI for Disaster Act

Sponsor: Bob Casey (D-Pa.)

H.R.4143: Dialysis PATIENTS Demonstration Act of 2017

Sponsor: Jason Smith (R-Mo.)

H.R.7217: IMPROVE Act

Sponsor: Joe L. Barton (R-Texas)

H.R.1425: Patient Protection and Affordable Care Enhancement Act

Sponsor: Angie Craig (D-Minn.)

H.R.1386: ENROLL Act of 2019

Sponsor: Kathy Castor (D-Fla.)

H.R.1385: SAVE Act

Sponsor: Andy Kim (D-N.J.)

S.340: CREATES Act of 2019

Sponsor: Patrick J. Leahy (D-Vt.)

H.R.965: CREATES Act of 2019

Sponsor: David Cicilline (D-R.I.)

S.317: Advancing Care for Exceptional Kids Act of 2019

Sponsor: Charles E. Grassley (R-Iowa)

H.R.1226: ACE Kids Act of 2019

Sponsor: Kathy Castor (D-Fla.)

H.R.1839: Medicaid Services Investment and Accountability Act of 2019

Sponsor: Raul Ruiz (D-Calif.)

H.R.1398: Health Insurance Tax Relief Act of 2019

Sponsor: Ami Bera (D-Calif.)

S.80: Jobs and Premium Protection Act

Sponsor: John Barrasso (R-Wyo.)

S.172: Health Insurance Tax Relief Act of 2019

Sponsor: Cory Gardner (R-Colo.)

H.R.1892: Quadrennial Homeland Security Review Technical Corrections Act of 2019

Sponsor: Bonnie Watson Coleman (D-N.J.)

H.R.987: Strengthening Health Care and Lowering Prescription Drug Costs Act

Sponsor: Lisa Blunt Rochester (D-Del.)

S.1895: Lower Health Care Costs Act

Sponsor: Lamar Alexander (R-Tenn.)

H.R.3630: No Surprises Act

Sponsor: Frank Pallone (D-N.J.)

H.R.2447: Jobs and Premium Protection Act

Sponsor: Anthony Brindisi (D-N.Y.)

H.R.3: Elijah E. Cummings Lower Drug Costs Now Act

Sponsor: Frank Pallone (D-N.J.)

H.R.1158: Consolidated Appropriations Act, 2020

Sponsor: Michael McCaul (R-Texas)

H.R.1865: Further Consolidated Appropriations Act, 2020

Sponsor: Bill Pascrell Jr. (D-N.J.)

H.R.4995: Maternal Health Quality Improvement Act of 2020

Sponsor: Eliot L. Engel (D-N.Y.)

H.R.4996: Helping MOMS Act of 2020

Sponsor: Robin Kelly (D-Ill.)

H.R.5281: Drug Price Transparency in Medicaid Act of 2019

Sponsor: Buddy Carter (R-Ga.)

H.R.3107: Improving Seniors' Timely Access to Care Act of 2019

Sponsor: Suzan K. DelBene (D-Wash.)

H.R.6201: Families First Coronavirus Response Act

Sponsor: Nita M. Lowey (D-N.Y.)

S.3031: Significant Transnational Criminal Organization Designation Act

Sponsor: Tom Cotton (R-Ark.)

H.R.6926: MIND Act

Sponsor: Brendan Boyle (D-Pa.)

S.2846: Protecting Patients Transportation to Care Act

Sponsor: Johnny Isakson (R-Ga.)

H.R.6800: The Heroes Act

Sponsor: Nita M. Lowey (D-N.Y.)

H.R.5304: PBM Transparency in Prescription Drug Costs Act

Sponsor: Kurt Schrader (D-Ore.)

S.1624: HEALS Act

Sponsor: John Cornyn (R-Texas)

H.R.7539: Strengthening Behavioral Health Parity Act

Sponsor: Joseph P. Kennedy III (D-Mass.)

H.R.133: Consolidated Appropriations Act, 2021

Sponsor: Henry Cuellar (D-Texas)

H.R.925: The Heroes Act

Sponsor: Mike Thompson (D-Calif.)

S.350: Competitive Health Insurance Reform Act of 2019

Sponsor: Steve Daines (R-Mont.)

H.R.1418: Competitive Health Insurance Reform Act of 2020

Sponsor: Peter A. DeFazio (D-Ore.)

H.R.133: David’s Law

Sponsor: Sheila Jackson Lee (D-Texas)

H.R.959: Black Maternal Health Momnibus Act of 2021

Sponsor: Lauren Underwood (D-Ill.)

H.R.3969: To amend title XXVII of the Public Health Service Act to include...

Sponsor: John Curtis (R-Utah)

H.R.3107: Helping to Encourage Real Opportunities (HERO) for Youth Act of 2021

Sponsor: Robin Kelly (D-Ill.)

H.R.4074: Addressing Social Determinants in Medicare Advantage Act of 2021

Sponsor: Gus Bilirakis (R-Fla.)

H.R.315: Medicare Sequester COVID Moratorium Act

Sponsor: Brad Schneider (D-Ill.)

S.748: Medicare Sequester Relief Act

Sponsor: Jeanne Shaheen (D-N.H.)

H.R.2166: Ensuring Parity in MA and PACE for Audio-Only Telehealth Act of 2021

Sponsor: Terri Sewell (D-Ala.)

S.150: Ensuring Parity in MA for Audio-Only Telehealth Act of 2021

Sponsor: Catherine Cortez Masto (D-Nev.)

H.R.4406: Supporting Medicaid in the U.S. Territories Act of 2021

Sponsor: Darren Soto (D-Fla.)

H.R.3: Elijah E. Cummings Lower Drug Costs Now Act

Sponsor: Frank Pallone (D-N.J.)

H.R.5376: Inflation Reduction Act of 2022

Sponsor: John Yarmuth (D-Ky.)

H.R.6833: Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023

Sponsor: Angie Craig (D-Minn.)

H.R.3447: Permanency for Audio-Only Telehealth Act

Sponsor: Jason Smith (R-Mo.)

H.R.1826: Fairness in Medicare Part B Enrollment Act of 2021

Sponsor: Jenniffer González-Colón (R-Puerto Rico)

H.R.2217: Territory Federal Matching Requirement Equity Act of 2021

Sponsor: Jenniffer González-Colón (R-Puerto Rico)

H.R.1825: Territories Medicare Prescription Drug Assistance Equality Act of 2021

Sponsor: Jenniffer González-Colón (R-Puerto Rico)

H.R.8133: Transparency of Hospital Billing Act

Sponsor: Victoria Spartz (R-Ind.)

H.R.7666: Restoring Hope for Mental Health and Well-Being Act of 2022

Sponsor: Frank Pallone (D-N.J.)

S.4293: Pharmacy Benefit Manager Transparency Act of 2022

Sponsor: Maria Cantwell (D-Wash.)

H.R.7997: Achieving Equity in the Treatment of Dual Eligible Beneficiaries Act

Sponsor: Jenniffer González-Colón (R-Puerto Rico)

H.R.7780: Mental Health Matters Act

Sponsor: Mark DeSaulnier (D-Calif.)

S.3778: Territories Medicare Prescription Drug Assistance Equity Act of 2022

Sponsor: Robert Menendez (D-N.J.)

H.R.5981: Telehealth Expansion Act of 2021

Sponsor: Michelle Steel (R-Calif.)

H.R.3173: Improving Seniors’ Timely Access to Care Act of 2021

Sponsor: Suzan K. DelBene (D-Wash.)

S.3018: Improving Seniors’ Timely Access to Care Act of 2021

Sponsor: Roger Marshall (R-Kan.)

H.R.8594: Restore Protections for Dialysis Patients Act

Sponsor: Yvette D. Clarke (D-N.Y.)

S.127: Pharmacy Benefit Manager Transparency Act of 2023

Sponsor: Maria Cantwell (D-Wash.)

H.R.2217: To provide for a limitation on availability of funds for Related...

Sponsor: Andy Biggs (R-Ariz.)

H.R.1825: Right to Try Clarification Act

Sponsor: Earl Blumenauer (D-Ore.)

H.R.1826: PSA Screening for HIM Act

Sponsor: Larry Bucshon (R-Ind.)

S.113: Prescription Pricing for the People Act of 2023

Sponsor: Charles E. Grassley (R-Iowa)

S.150: Affordable Prescriptions for Patients Act of 2023

Sponsor: John Cornyn (R-Texas)

H.R.3417: FAIR Act

Sponsor: Kevin Hern (R-Okla.)

S.1869: SITE Act

Sponsor: Mike Braun (R-Ind.)

H.R.824: Telehealth Benefit Expansion for Workers Act of 2023

Sponsor: Tim Walberg (R-Mich.)

H.R.4221: Healthcare for Our Troops Act

Sponsor: Andy Kim (D-N.J.)

H.R.3799: CHOICE Arrangement Act

Sponsor: Kevin Hern (R-Okla.)

H.R.4027: Fairness in Medicare Part B Enrollment Act of 2023

Sponsor: Jenniffer González-Colón (R-Puerto Rico)

H.R.4411: Medicare Advantage Integrity Act of 2023

Sponsor: Jenniffer González-Colón (R-Puerto Rico)

H.R.4410: Fairness in Medicare Savings Program Act of 2023

Sponsor: Jenniffer González-Colón (R-Puerto Rico)

S.1339: Pharmacy Benefit Manager Reform Act

Sponsor: Bernard Sanders (ID-Vt.)

H.R.3281: Transparent PRICE Act

Sponsor: Cathy McMorris Rodgers (R-Wash.)

S.1269: INSULIN Act of 2023

Sponsor: Jeanne Shaheen (D-N.H.)

H.R.2880: Protecting Patients Against PBM Abuses Act

Sponsor: Buddy Carter (R-Ga.)

H.R.2679: Pharmacy Benefits Manager Accountability Act

Sponsor: Ann McLane Kuster (D-N.H.)

H.R.1613: Drug Price Transparency in Medicaid Act of 2023

Sponsor: Buddy Carter (R-Ga.)

H.R.3760: To amend title VII of the Public Health Service Act to strengthen the...

Sponsor: Troy Carter (D-La.)

H.R.4509: Transparency in Billing Act of 2023

Sponsor: Virginia Foxx (R-N.C.)

H.R.4507: Transparency in Coverage Act of 2023

Sponsor: Robert Good (R-Va.)

H.R.4527: Health DATA Act of 2023

Sponsor: Lori Chavez-DeRemer (R-Ore.)

H.R.4508: Hidden Fee Disclosure Act of 2023

Sponsor: Joe Courtney (D-Conn.)

H.R.4822: Health Care Price Transparency Act of 2023

Sponsor: Jason Smith (R-Mo.)

H.R.3561: PATIENT Act of 2023

Sponsor: Cathy McMorris Rodgers (R-Wash.)

H.R.5378: Lower Costs, More Transparency Act

Sponsor: Cathy McMorris Rodgers (R-Wash.)

S.2840: Bipartisan Primary Care and Health Workforce Act

Sponsor: Bernard Sanders (ID-Vt.)

H.R.1843: Telehealth Expansion Act of 2023

Sponsor: Michelle Steel (R-Calif.)

S.1967: PBM Act

Sponsor: Robert Menendez (D-N.J.)

H.R.3520: Veteran Care Improvement Act of 2023

Sponsor: Mariannette Miller-Meeks (R-Iowa)

S.2649: Making Community Care Work for Veterans Act of 2023

Sponsor: Jon Tester (D-Mont.)

H.R.2670: National Defense Authorization Act for Fiscal Year 2024

Sponsor: Mike D. Rogers (R-Ala.)

H.R.5396: Coverage Determination Clarity Act of 2023

Sponsor: Larry Bucshon (R-Ind.)

S.2305: Biosimilar Red Tape Elimination Act

Sponsor: Mike Lee (R-Utah)

H.R.6283: DRUG Act

Sponsor: Mariannette Miller-Meeks (R-Iowa)

S.2973: Modernizing and Ensuring PBM Accountability Act

Sponsor: Ron Wyden (D-Ore.)

H.R.1790: Biologics Competition Act of 2023

Sponsor: Mariannette Miller-Meeks (R-Iowa)

S.1250: Drug-price Transparency for Consumers Act of 2023

Sponsor: Richard J. Durbin (D-Ill.)

Show All Mentioned Bills

Lobbyists

Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.

Lobbyist	Covered positions?
Kim Zimmerman	Legislative Assistant, Sen. Ben Nelson
*continued* *continued*	Research Analyst, US Department of Justice Legislative Correspondent/Assistant, Sen. Tom Harkin Director/Advisor Health Policy, Sen. Bill Frist Director of Policy/LA/LC, Sen. Chuck Hagel Comm. Dir./Senior LA, Rep. Sherwood Boehlert Leg. Correspondent/Assistant, Sen. Tom Harkin Leg. Correspondent/Assistant., Sen. Tom Harkin Leg. Correspondent/Asst., Sen. Tom Harkin
Stephen Northrup	Health Policy Director, Senate HELP Committee Health Policy Director, Senate Help Committee
Elizabeth Hall	Director, Office of Legislation, CMS
Samuel Marchio	Chief of Staff, Rep. Michael Arcuri
Gabriella Fahrer	Senate Armed Services Committee (Counsel)
Patrick Velliky	Humana Health Insurance Legislative Director, Office of Congressman Jim Renacci (R-OH)
James Stursberg	Staff Assistant, Rep. Ander Crenshaw (July 2014-June 2015)
Timothy Drumm	Chief of Staff, fmr. Rep. Ann Marie Buerkle (NY-25) Legislative / Appropriations Assistant, fmr. James T. Walsh (NY-25) Chief of Staff, fmr. Rep. Ann Marie Buerkle (NY-25) Legislative / Appropriations Assistant, fmr. James T. Walsh (NY-25)
Judith Langer	n/a
Carolyn Hicks	n/a
Jerry Steffl	n/a
Brian Munroe	n/a
Adam Goldberg	n/a
Mary K. Zirkelbach	n/a
Erika Long	n/a
Carolyn Hicks Mayle	n/a
Brian Coyne	n/a
Caroyln Hicks Mayle	n/a
AMY ODOM	n/a
Catherine Nabavi	n/a
Sam Marchio	n/a
Jonathan Bonet-Rivera	n/a
Simone Myrie	n/a

Disclosures Filed

Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.

1st Quarter, 2024

Q1 Report

In Q1, Elevance Health, Inc. had in-house lobbyists. The report was filed on April 22. Original Filing: 301574373.xml

Lobbying Issues

Prior Authorization Mental Health and Substance Use Behavioral Health Crisis Intervention 9-8-8 hotline services Mental Health Parity Facilitating Accountability in Reimbursements Act (FAIR Act) (H.R. 3417) Site-based Invoicing and Transparency Enhancement (SITE) Act (S.1869) Lower Cost, More Transparency Act (H.R. 5378) Primary Care and Workforce Act (S. 2840) AI Use in Healthcare Health Disparities, including Maternal Health and Rural Health H.R. 3520 Veteran Care Improvement Act of 2023. Making Community Care Work for Veterans Act of 2023 (S.2649) Dept. of Defense Military OneSource Program H.R. 2670 FY2024 National Defense Authorization Act of 2024 Provider Directories Transparency in Coverage and Machine-Readable Files Affordable Connectivity Program Change Healthcare Cyber Incident

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2023

Q4 Report

In Q4, Elevance Health, Inc. had in-house lobbyists. The report was filed on Jan. 22. Original Filing: 301538899.xml

Lobbying Issues

Prior Authorization Mental Health and Substance Use Behavioral Health Crisis Intervention 9-8-8 hotline services Mental Health Parity Facilitating Accountability in Reimbursements Act (FAIR Act) (H.R. 3417) Site-based Invoicing and Transparency Enhancement (SITE) Act (S.1869) Lower Cost, More Transparency Act (H.R. 5378) Primary Care and Workforce Act (S. 2840) AI Use in Healthcare Health Disparities, including Maternal Health and Rural Health H.R. 3520 Veteran Care Improvement Act of 2023. Making Community Care Work for Veterans Act of 2023 (S.2649) Dept. of Defense Military OneSource Program H.R. 2670 FY2024 National Defense Authorization Act of 2024 Better Mental Health Care, Lower-Cost Drugs and Extenders Act Provider Directories Transparency in Coverage and Machine-Readable Files

Agencies Lobbied

Type of Issue

Lobbying Issues

Prior Authorization Mental Health and Substance Use Behavioral Health Crisis Intervention 9-8-8 hotline services Mental Health Parity Facilitating Accountability in Reimbursements Act (FAIR Act) (H.R. 3417) Site-based Invoicing and Transparency Enhancement (SITE) Act (S.1869) Lower Cost, More Transparency Act (H.R. 5378) Primary Care and Workforce Act (S. 2840) AI Use in Healthcare Health Disparities, including Maternal Health and Rural Health H.R. 3520 Veteran Care Improvement Act of 2023. Making Community Care Work for Veterans Act of 2023 (S.2649) Dept. of Defense Military OneSource Program H.R. 2670 FY2024 National Defense Authorization Act of 2024 Better Mental Health Care, Lower-Cost Drugs and Extenders Act Provider Directories Transparency in Coverage and Machine-Readable Files

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2023

Amendment

Elevance Health, Inc. amended a lobbying report for in-house lobbying in Q32023 on Nov. 6, 2023 Original Filing: 301518442.xml

Lobbying Issues

Individual Market Prior Authorization Mental Health and Substance Use, Behavioral Health Crisis Intervention and 9-8-8 hotline services Mental Health Parity Fair Hospital Billing and Claims Form Issues Facilitating Accountability in Reimbursements Act (FAIR Act) (H.R. 3417) Site-based Invoicing and Transparency Enhancement (SITE) Act (S.1869) Mental Health Workforce Act (H.R. 3760) Transparency in Billing Act (H.R. 4509) Transparency in Coverage Act (H.R. 4507) Health Data Act (H.R. 4527) Hidden Fee Disclosure Act (H.R. 4508) The Health Care Price Transparency Act of 2023 (H.R. 4822) PATIENT Act (H.R. 3561) Lower Cost, More Transparency Act (H.R. 5378) Primary Care and Workforce Act (S. 2840) BCBSA of Louisiana Acquisition AI Use in Healthcare Health Disparities, including Maternal Health and Rural Health Veterans Health - Veterans Community Care program Military OneSource program

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2023

Q3 Report

In Q3, Elevance Health, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2023. Original Filing: 301515170.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2023

Q2 Report

In Q2, Elevance Health, Inc. had in-house lobbyists. The report was filed on July 20, 2023. Original Filing: 301490934.xml

Lobbying Issues

ACA 1332 Waivers Individual Market and Exchange Stabilization Prior Authorization Dishonest and Fair Hospital Billing Transparency in Billing Act Facilitating Accountability in Reimbursements Act (FAIR Act) (H.R. 3417) Site-based Invoicing and Transparency Enhancement (SITE) Act (S.1869) Protecting Health Care for All Patients (PATIENTS) Act of 2022 (H.R. 7634) BCBSA of Louisiana Acquisition Flexibility in Hospital Ownership Act Oversight of Anti-Competitive Behavior of Non-Profit Hospitals Act Addressing Anti-Competitive Contracting Clauses Act Hospital Claims Form Issues Privacy and Healthcare Cybersecurity Social Determinants of Health (SDOH) Behavioral Health Crisis Intervention and 9-8-8 hotline services MAT Act Chronic Kidney Disease Conditions of Coverage Reform Telehealth Benefit Expansion for Workers Act of 2023 (H.R.824 ) Special Enrollment Periods Medicaid Eligibility and Renewals Veterans Affairs Community Care Network Program Veterans PACT Act Defense - Military OneSource Program; H.R. 4221 - an Act to eliminate certain health care charges for members of the Selected Reserve eligible for TRICARE Reserve Select Insurance Navigators Network Adequacy Provider Directories Provider and Nursing Licensing Issues Inpatient Only List Association Health Plans (CHOICE Arrangement Act (H.R. 3799) Machine Readable Files Cancer Moonshot Initiative AI Use in Healthcare

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Medicare Advantage (risk adjustment, coding intensity, encounter data, dual-eligible members, star ratings, extreme and uncontrollable circumstances policy, normalization factors, stars contract consolidation) Mental Health and Substance Use (42 CFR Part 2) Medicaid Managed Care Medicare Site Neutrality Site-based Invoicing and Transparency Enhancement (SITE) Act (S.1869) Protecting Health Care for All Patients (PATIENTS) Act of 2022 (H.R. 7634) Medicaid Actuarial Soundness Pharmacy Benefit Manager (PBM) Operations and Practices, Spread Pricing Social Determinants of Health (SDOH) Health Equity/Health Disparities Maternal health (Medicaid postpartum coverage extension, Black Maternal Health) Medicare Savings Program (MSP) in Medicaid H.R. 7997, Increasing Medicare Advantage Benchmark Rates in Puerto Rico and other regions with low Medicare fee-for-service penetration and to make the Medicare Savings Program available in all jurisdictions Medicaid funding for Puerto Rico H.R. 2217 (Territory Federal Matching Requirement Equity Act of 2021) H.R. 1825 (A Bill to Remove the Matching Requirement for Medicare Part D Drugs) H.R. 1826 (Fairness in Medicare Part B Enrollment Act) S. 3778 (Territories Medicare Prescription Drug Assistance Equity Act of 2022) Medicare Part B penalties (H.R. 4027) Medicare Advantage reimbursement (H.R. 4411) Medicare Savings Program (H.R. 4410) Medicaid Eligibility and Renewals Medicare Advantage Supplemental Benefits Mental Health Parity 2024 Notice of Benefit and Payment Parameters CY2024 Medicare Advantage Advance Notice and Part D Program Medicaid and CHIP Managed Care Access, Finance, and Quality Proposed Rule Direct and Indirect Remuneration

Agencies Lobbied

Type of Issue

Lobbying Issues

Biosimilar Red Tape Elimination Act Biologics Competition Act Price of prescription drugs; antitrust issues; Affordable Prescriptions for Patients Act of 2023 (S.150) Pharmacy Benefit Manager (PBM) operations and practices, Spread Pricing Drug Patent Reform Robinson-Patman Act Reform Pharmacy Benefit Manager Transparency Act (S. 127) PBM Transparency Language in the Restoring Hope for Mental Health and Well-Being Act of 2022 (H.R.7666) Rebates and Rebate Pass Through Prescription Pricing for the People Act (S. 113) Price of Prescription Drugs Pharmacy Benefit Manager (PBM) Operations and Practices, Spread Pricing Pharmacy Benefit Managers; Pharmacy Benefit Manager Reform Act (S. 1339) Transparency PRICE Act (H.R. 3281) Protecting Health Care for All Patients (PATIENTS) Act of 2022 (H.R. 7634) INSULIN Act of 2023 (S. 1269) Insulin Commercial Price Cap Protecting Patients Against PBM Abuses Act (H.R. 2880) Pharmacy Benefits Manager Accountability Act (H.R. 2679) Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613)

Agencies Lobbied

Type of Issue

1st Quarter, 2023

Q1 Report

In Q1, Elevance Health, Inc. had in-house lobbyists. The report was filed on April 20, 2023. Original Filing: 301466497.xml

Lobbying Issues

ACA 1332 Waivers Individual Market and Exchange Stabilization Prior Authorization COVID-19 Testing, Vaccinations, Cost Sharing for COVID-19 Testing, End of the PHE Transparency of Hospital Billing Act (H.R.8133) BCBSA of Louisiana Acquisition Flexibility in Hospital Ownership Act Oversight of Anti-Competitive Behavior of Non-Profit Hospitals Act Hospital Claims Form Issues Privacy and Healthcare Cybersecurity Social Determinants of Health (SDOH) Behavioral Health Crisis Intervention and 9-8-8 hotline services MAT Act Price of Prescription Drugs Pharmacy Benefit Manager (PBM) Operations and Practices, Spread Pricing Pharmacy Benefit Manager Transparency Act (S. 127) Chronic Kidney Disease Conditions of Coverage Reform Telehealth Expansion Act (H.R. 5981) Special Enrollment Periods Medicaid Eligibility and Renewals VA Community Care Network Program Veterans PACT Act Insurance Navigators Network Adequacy Provider Directories Provider and Nursing Licensing Issues Inpatient Only List

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Medicare Advantage (risk adjustment, coding intensity, encounter data, dual-eligible members, star ratings, extreme and uncontrollable circumstances policy, normalization factors, stars contract consolidation) Mental Health and Substance Use (42 CFR Part 2) Medicaid Managed Care Site Neutrality Medicaid Actuarial Soundness Pharmacy Benefit Manager (PBM) Operations and Practices, Spread Pricing Social Determents of Health (SDOH) Health Equity/Health Disparities Maternal health (Medicaid postpartum coverage extension, Black Maternal Health) Medicare Savings Program (MSP) in Medicaid H.R. 7997, Increasing Medicare Advantage Benchmark Rates in Puerto Rico and other regions with low Medicare fee-for-service penetration and to make the Medicare Savings Program available in all jurisdictions Medicaid funding for Puerto Rico H.R. 2217 (Territory Federal Matching Requirement Equity Act of 2021) H.R. 1825 (A Bill to Remove the Matching Requirement for Medicare Part D Drugs) H.R. 1826 (Fairness in Medicare Part B Enrollment Act) S. 3778 (Territories Medicare Prescription Drug Assistance Equity Act of 2022). Medicaid Eligibility and Renewals Medicare Advantage Supplemental Benefits Mental Health Parity 2024 Notice of Benefit and Payment Parameters CY2024 Medicare Advantage Advance Notice and Part D Program

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2022

Q4 Report

In Q4, Elevance Health, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2023. Original Filing: 301442369.xml

Lobbying Issues

ACA 1332 Waivers Individual Market and Exchange Stabilization Prior Authorization Hospital Consolidation Transparency of Hospital Billing Act (H.R.8133) Flexibility in Hospital Ownership Act Oversight of Anti-Competitive Behavior of Non-Profit Hospitals Act Consumer Choice of Care Act Competition in State Healthcare Markets Act Addressing Anti-Competitive Contracting Clauses Act Increasing Competition for Medical Residency Act Hospital Claims Form Issues Privacy and Healthcare Cybersecurity Social Determinants of Health (SDOH) To amend title XXVII of the Public Health Service Act to include activities to address social determinants of health in the calculation of medical loss ratios. (H.R.3969) Mental Health and Substance Use, CFR Part 2, Parity and MHPAEA Compliance Issues Mental Health Matters Act (H.R. 7780) Restoring Hope for Mental Health and Well-Being Act of 2022 (H.R.7666) Behavioral Health Crisis Intervention and 9-8-8 hotline services Bipartisan Safer Communities Act MAT Act Surprise Medical Billing Price of Prescription Drugs Pharmacy Benefit Manager (PBM) Operations and Practices, Spread Pricing, Pharmacy Benefit Manager Transparency Act (S. 4293) Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act Chronic Kidney Disease Conditions of Coverage Reform COVID-19 Testing, Vaccines, Treatment, Cost Sharing Medicare Sequestration Telehealth KEEP Telehealth Options Act Telehealth Expansion Act (H.R. 5981) Short Term Limited Duration Health Plans Consolidated Appropriations Act (H.R. 133) Medical Loss Ratio Federal Medical Assistance Percentages (FMAP) increase Special Enrollment Periods Hospital Claims Form Issues Build Back Better Act (H.R.5376) Inflation Reduction Act of 2022 Medicaid Eligibility Health Equity/Health Disparities Defense Health Programs (FY2022 Budget and FY2023 Budget Request) Veterans Health Care VA Community Care Network Program Veterans PACT Act Sergeant First Class Heath Robinson Honoring our Promise to Address Comprehensive Toxics Act of 2022 Achieving Equity in the Treatment of Dual Eligible Beneficiaries Act (H.R. 7997) TCPA Insurance Navigators Network Adequacy Provider Directories 2023 Omnibus Appropriations Bill Originating Site Requirements Provider and Nursing Licensing Issues Inpatient Only List Site Neutrality Biosimilar Red Tape Elimination Act Biologics Competition Act

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Medicare Advantage (risk adjustment, coding intensity, encounter data, dual-eligible members, star ratings, extreme and uncontrollable circumstances policy, normalization factors, stars contract consolidation, ESRD, audio-only telehealth) Medicare RAD-V Mental Health and Substance Use (42 CFR Part 2) Medicaid Managed Care Medicaid Expansion Medicaid Reform Medicaid Redeterminations CHIP Reauthorization Medicaid Actuarial Soundness Long-term Services and Supports Medicare Part D prescription drug program Medicare Advantage Pilot Program in TRICARE Pharmacy Benefit Manager (PBM) Operations and Practices, Spread Pricing Direct and Indirect Remuneration (DIR) reforms in the FY 2023 Medicare Part D Notice Affordable Insulin Now Act (H.R.6833) Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act Restoring Hope for Mental Health and Well-Being Act of 2022 (H.R.7666) Social Determents of Health (SDOH) Addressing Social Determinants in Medicare Advantage Act of 2021 (H.R.4074) Health Equity/Health Disparities Maternal health (Medicaid postpartum coverage extension, H.R.959 Black Maternal Health Momnibus Act of 2021) Helping MOMS Act of 2021 Medicare Audio-Only Telehealth (H.R.2166, S.150) Medicaid Funding for Puerto Rico Medicare Savings Program (MSP) in Medicaid Increasing on the Medicare Advantage Benchmarks to a Minimum Level H.R. 7997 (to Amend the SS Act to establish a floor in MA benchmark rates for regions with low Medicare fee-for-service penetration and to make the Medicare Savings Program available in all jurisdictions) H.R. 2217 (Territory Federal Matching Requirement Equity Act of 2021) H.R. 1825 (A Bill to Remove the Matching Requirement for Medicare Part D Drugs) H.R. 1826 (Fairness in Medicare Part B Enrollment Act) S. 3778 (Territories Medicare Prescription Drug Assistance Equity Act of 2022). Build Back Better Act (H.R.5376) Medicaid Eligibility and Redeterminations Inflation Reduction Act of 2022 (H.R. 5376) Medicare Advantage Supplemental Benefits Timely Access to Care Act (H.R. 3173 and S. 3018) 2023 Omnibus Appropriations Bill Mental Health Parity Restore Protections for Dialysis Patients Act (H.R.8594)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2022

Q3 Report

In Q3, Elevance Health, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2022. Original Filing: 301418658.xml

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (individual mandate, cost sharing reduction subsidies, reinsurance transitional policies) ACA 1332 Waivers Individual market and exchange stabilization Prior authorization Hospital Consolidation Transparency of Hospital Billing Act (H.R.8133) Flexibility in Hospital Ownership Act Oversight of Anti-Competitive Behavior of Non-Profit Hospitals Act Consumer Choice of Care Act Competition in State Healthcare Markets Act Addressing Anti-Competitive Contracting Clauses Act Increasing Competition for Medical Residency Act Privacy and Healthcare Cybersecurity Social Determinants of Health (SDOH) Mental health and substance use, CFR Part 2, Parity and compliance issues H.R. 7780 - Mental Health Matters Act Restoring Hope for Mental Health and Well-Being Act of 2022 (H.R.7666) Behavioral Health Crisis Intervention and 9-8-8 hotline services Mental health parity and MHPAEA compliance Surprise medical billing Price of prescription drugs Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing, Pharmacy Benefit Manager Transparency Act (S. 4293) Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act Chronic Kidney Disease Conditions of Coverage Reform COVID-19 testing, vaccines, treatment, cost sharing Medicare Sequestration, ACA subsidies, COVID vaccines and testing, Consolidated Appropriations Act Telehealth KEEP Telehealth Options Act Short Term Limited Duration health plans Consolidated Appropriations Act (H.R. 133) Medical Loss Ratio Federal Medical Assistance Percentages (FMAP) increase Special Enrollment Period Hospital Claims Form Issues Build Back Better Act (H.R.5376) Inflation Reduction Act of 2022 Medicaid eligibility Health Equity/Health Disparities Defense Health Programs (FY2022 Budget and FY2023 Budget Request) Veterans Health Care Veterans PACT Act Sergeant First Class Heath Robinson Honoring our Promise to Address Comprehensive Toxics Act of 2022 Achieving Equity in the Treatment of Dual Eligible Beneficiaries Act (H.R. 7997) TCPA Insurance Navigators Network Adequacy Provider Directories Bipartisan Safer Communities Act

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Medicare Advantage (risk adjustment, coding intensity, encounter data, dual-eligible members, star ratings, extreme and uncontrollable circumstances policy, normalization factors, stars contract consolidation, ESRD, audio-only telehealth) Medicare RAD-V Mental health and substance use (42 CFR Part 2) Medicaid managed care (IMD Exclusion) Medicaid expansion Medicaid reform (block grants, per capita caps) Medicaid and CHIP reauthorization Medicaid actuarial soundness Long-term services and supports Medicare Part D prescription drug program and Medicare Part D coverage gap (donut hole) Opioid addiction issues and response (prescription drug monitoring programs) Medicaid medical loss ratio remittance Medicare Advantage Pilot Program in TRICARE Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing Direct and Indirect Remuneration (DIR) reforms in the FY 2023 Medicare Part D Notice H.R.6833 - Affordable Insulin Now Act Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act H.R.7666 - Restoring Hope for Mental Health and Well-Being Act of 2022 Social Determents of Health (SDOH) H.R.4074 - Addressing Social Determinants in Medicare Advantage Act of 2021 Health Equity/Health Disparities Maternal health (Medicaid postpartum coverage extension, H.R.959 Black Maternal Health Momnibus Act of 2021) Helping MOMS Act of 2021 Medicare Audio-Only Telehealth (H.R.2166, S.150) Continuing Resolution (CR)FY 2022 Medicaid Funding for Puerto Rico Medicare Savings Program (MSP) in Medicaid Increasing on the Medicare Advantage benchmarks to a minimum level H.R. 7997 (to Amend the SS Act to establish a floor in MA benchmark rates for regions with low Medicare fee-for-service penetration and to make the Medicare Savings Program available in all jurisdictions) H.R. 2217 (Territory Federal Matching Requirement Equity Act of 2021) H.R. 1825 (A Bill to Remove the Matching Requirement for Medicare Part D Drugs) H.R. 1826 (Fairness in Medicare Part B Enrollment Act) S. 3778 (Territories Medicare Prescription Drug Assistance Equity Act of 2022). H.R.5376 - Build Back Better Act Medicaid eligibility and redeterminations H.R. 5376 - Inflation Reduction Act of 2022 Medicare Advantage Supplemental Benefits

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2022

Amendment

Elevance Health, Inc., formerly reported as Anthem, Inc. amended a lobbying report for in-house lobbying in Q22022 on Oct. 20, 2022 Original Filing: 301418613.xml

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (individual mandate, cost sharing reduction subsidies, reinsurance transitional policies) ACA 1332 Waivers Individual market and exchange stabilization Prior authorization Hospital Consolidation Transparency of Hospital Billing Act (H.R.8133) Privacy and Healthcare Cybersecurity Social Determinants of Health (SDOH) Mental health and substance use, Parity and compliance issues. Restoring Hope for Mental Health and Well-Being Act of 2022 (H.R.7666) Behavioral Health Crisis Intervention and 9-8-8 hotline services Mental health parity and MHPAEA compliance Surprise medical billing; Price of prescription drugs Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing, Pharmacy Benefit Manager Transparency Act (S. 4293) Chronic Kidney Disease Conditions of Coverage Reform COVID-19 testing, vaccines, treatment, cost sharing Medicare Sequestration, ACA subsidies, COVID vaccines and testing, Consolidated Appropriations Act Behavioral Health Telehealth Short Term Limited Duration health plans Consolidated Appropriations Act (H.R. 133) Medical Loss Ratio; To amend title XXVII of the Public Health Service Act to include activities to address social determinants of health in the calculation of medical loss ratios (H.R. 3969) Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act Federal Medical Assistance Percentages (FMAP) increase Special Enrollment Period CONNECT for Health Act Hospital Claims Form Issues Build Back Better Act (H.R.5376) KEEP Telehealth Options Act Agent/broker compensation disclosures under the Consolidated Appropriations Act. CAA regulation implementation Hospital Competition Act Medicaid eligibility Health Equity/Health Disparities Postal Service Reform Act of 2022 Defense Health Programs (FY2022 Budget and FY2023 Budget Request) Veterans Health Care (U.S. Department of Veterans Affairs Assets and Infrastructure Review Report) 2018 MISSION Act Veterans PACT Act Achieving Equity in the Treatment of Dual Eligible Beneficiaries Act (H.R. 7997) Bipartisan Safer Communities Act

Agencies Lobbied

Type of Issue

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (individual mandate, cost sharing reduction subsidies, reinsurance transitional policies) ACA 1332 Waivers Individual market and exchange stabilization Prior authorization Hospital Consolidation Transparency of Hospital Billing Act (H.R.8133) Privacy and Healthcare Cybersecurity Social Determinants of Health (SDOH) Mental health and substance use, Parity and compliance issues. Restoring Hope for Mental Health and Well-Being Act of 2022 (H.R.7666) Behavioral Health Crisis Intervention and 9-8-8 hotline services Mental health parity and MHPAEA compliance Surprise medical billing; Price of prescription drugs Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing, Pharmacy Benefit Manager Transparency Act (S. 4293) Chronic Kidney Disease Conditions of Coverage Reform COVID-19 testing, vaccines, treatment, cost sharing Medicare Sequestration, ACA subsidies, COVID vaccines and testing, Consolidated Appropriations Act Behavioral Health Telehealth Short Term Limited Duration health plans Consolidated Appropriations Act (H.R. 133) Medical Loss Ratio; To amend title XXVII of the Public Health Service Act to include activities to address social determinants of health in the calculation of medical loss ratios (H.R. 3969) Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act Federal Medical Assistance Percentages (FMAP) increase Special Enrollment Period CONNECT for Health Act Hospital Claims Form Issues Build Back Better Act (H.R.5376) KEEP Telehealth Options Act Agent/broker compensation disclosures under the Consolidated Appropriations Act. CAA regulation implementation Hospital Competition Act Medicaid eligibility Health Equity/Health Disparities Postal Service Reform Act of 2022 Defense Health Programs (FY2022 Budget and FY2023 Budget Request) Veterans Health Care (U.S. Department of Veterans Affairs Assets and Infrastructure Review Report) 2018 MISSION Act Veterans PACT Act Achieving Equity in the Treatment of Dual Eligible Beneficiaries Act (H.R. 7997) Bipartisan Safer Communities Act

Agencies Lobbied

Type of Issue

Lobbying Issues

Medicare Advantage (risk adjustment, coding intensity, encounter data, dual-eligible members, star ratings, extreme and uncontrollable circumstances policy, normalization factors, stars contract consolidation, ESRD, audio-only telehealth H.R. 4074 -To amend title XVIII of the Social Security Act Medicare RAD-V Mental health and substance use (42 CFR Part 2) Medicaid (IMD Exclusion) Medicaid expansion Medicaid reform (block grants, per capita caps) Medicaid and CHIP reauthorization Medicaid actuarial soundness Long-term services and supports Social Determents of Health (SDOH) Medicare Part D prescription drug program and Medicare Part D coverage gap (donut hole) Opioid addiction issues and response (prescription drug monitoring programs) Medicaid medical loss ratio remittance Medicare Advantage Pilot Program in TRICARE Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing Against Direct and Indirect Remuneration (DIR) reforms in the FY 2023 Medicare Part D Notice H.R.6833 - Affordable Insulin Now Act Maternal health (Medicaid postpartum coverage extension, H.R.959 Black Maternal Health Momnibus Act of 2021) Helping MOMS Act of 2021 CMS Extreme & Uncontrollable Circumstances Policy Medicare Sequester (H.R.315, S.748) Medicare Audio-Only Telehealth (H.R.2166, S.150) Continuing Resolution (CR)FY 2022 Medicaid Funding for Puerto Rico Medicaid Funding for Puerto Rico including discussions on the FMAP, ESRD, and LTSS. Medicare Advantage issues such as rates, benchmarks, providers payments, and disparities in funding for territories. Medicare Advantage asks regarding the underfunding and disparity for Puerto Rico H.R.5376 - Build Back Better Act Medicaid eligibility Health Equity/Health Disparities

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2022

Q2 Report

In Q2, Elevance Health, Inc., formerly reported as Anthem, Inc. had in-house lobbyists. The report was filed on July 20, 2022. Original Filing: 301394461.xml

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (individual mandate, cost sharing reduction subsidies, reinsurance transitional policies) ACA 1332 Waivers Individual market and exchange stabilization Prior authorization Hospital Consolidation Transparency of Hospital Billing Act (H.R.8133) Privacy and Healthcare Cybersecurity Social Determinants of Health (SDOH) Mental health and substance use, Parity and compliance issues. Restoring Hope for Mental Health and Well-Being Act of 2022 (H.R.7666) Behavioral Health Crisis Intervention and 9-8-8 hotline services Mental health parity and MHPAEA compliance Surprise medical billing; Price of prescription drugs Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing, Pharmacy Benefit Manager Transparency Act (S. 4293) Chronic Kidney Disease Conditions of Coverage Reform COVID-19 testing, vaccines, treatment, cost sharing Medicare Sequestration, ACA subsidies, COVID vaccines and testing, Consolidated Appropriations Act Behavioral Health Telehealth Short Term Limited Duration health plans Consolidated Appropriations Act (H.R. 133) Medical Loss Ratio; To amend title XXVII of the Public Health Service Act to include activities to address social determinants of health in the calculation of medical loss ratios (H.R. 3969) Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act Federal Medical Assistance Percentages (FMAP) increase Special Enrollment Period CONNECT for Health Act Hospital Claims Form Issues Build Back Better Act (H.R.5376) KEEP Telehealth Options Act Agent/broker compensation disclosures under the Consolidated Appropriations Act. CAA regulation implementation Hospital Competition Act Medicaid eligibility Health Equity/Health Disparities Postal Service Reform Act of 2022 Defense Health Programs (FY2022 Budget and FY2023 Budget Request) Veterans Health Care (U.S. Department of Veterans Affairs Assets and Infrastructure Review Report) 2018 MISSION Act Veterans PACT Act Achieving Equity in the Treatment of Dual Eligible Beneficiaries Act (H.R. 7997) Bipartisan Safer Communities Act

Agencies Lobbied

Type of Issue

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (individual mandate, cost sharing reduction subsidies, reinsurance transitional policies) ACA 1332 Waivers Individual market and exchange stabilization Prior authorization Hospital Consolidation Transparency of Hospital Billing Act (H.R.8133) Privacy and Healthcare Cybersecurity Social Determinants of Health (SDOH) Mental health and substance use, Parity and compliance issues. Restoring Hope for Mental Health and Well-Being Act of 2022 (H.R.7666) Behavioral Health Crisis Intervention and 9-8-8 hotline services Mental health parity and MHPAEA compliance Surprise medical billing; Price of prescription drugs Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing, Pharmacy Benefit Manager Transparency Act (S. 4293) Chronic Kidney Disease Conditions of Coverage Reform COVID-19 testing, vaccines, treatment, cost sharing Medicare Sequestration, ACA subsidies, COVID vaccines and testing, Consolidated Appropriations Act Behavioral Health Telehealth Short Term Limited Duration health plans Consolidated Appropriations Act (H.R. 133) Medical Loss Ratio; To amend title XXVII of the Public Health Service Act to include activities to address social determinants of health in the calculation of medical loss ratios (H.R. 3969) Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act Federal Medical Assistance Percentages (FMAP) increase Special Enrollment Period CONNECT for Health Act Hospital Claims Form Issues Build Back Better Act (H.R.5376) KEEP Telehealth Options Act Agent/broker compensation disclosures under the Consolidated Appropriations Act. CAA regulation implementation Hospital Competition Act Medicaid eligibility Health Equity/Health Disparities Postal Service Reform Act of 2022 Defense Health Programs (FY2022 Budget and FY2023 Budget Request) Veterans Health Care (U.S. Department of Veterans Affairs Assets and Infrastructure Review Report) 2018 MISSION Act Veterans PACT Act Achieving Equity in the Treatment of Dual Eligible Beneficiaries Act (H.R. 7997) Bipartisan Safer Communities Act

Agencies Lobbied

Type of Issue

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (individual mandate, cost sharing reduction subsidies, reinsurance transitional policies) ACA 1332 Waivers Individual market and exchange stabilization Prior authorization Hospital Consolidation Transparency of Hospital Billing Act (H.R.8133) Privacy and Healthcare Cybersecurity Social Determinants of Health (SDOH) Mental health and substance use, Parity and compliance issues. Restoring Hope for Mental Health and Well-Being Act of 2022 (H.R.7666) Behavioral Health Crisis Intervention and 9-8-8 hotline services Mental health parity and MHPAEA compliance Surprise medical billing; Price of prescription drugs Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing, Pharmacy Benefit Manager Transparency Act (S. 4293) Chronic Kidney Disease Conditions of Coverage Reform COVID-19 testing, vaccines, treatment, cost sharing Medicare Sequestration, ACA subsidies, COVID vaccines and testing, Consolidated Appropriations Act Behavioral Health Telehealth Short Term Limited Duration health plans Consolidated Appropriations Act (H.R. 133) Medical Loss Ratio; To amend title XXVII of the Public Health Service Act to include activities to address social determinants of health in the calculation of medical loss ratios (H.R. 3969) Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act Federal Medical Assistance Percentages (FMAP) increase Special Enrollment Period CONNECT for Health Act Hospital Claims Form Issues Build Back Better Act (H.R.5376) KEEP Telehealth Options Act Agent/broker compensation disclosures under the Consolidated Appropriations Act. CAA regulation implementation Hospital Competition Act Medicaid eligibility Health Equity/Health Disparities Postal Service Reform Act of 2022 Defense Health Programs (FY2022 Budget and FY2023 Budget Request) Veterans Health Care (U.S. Department of Veterans Affairs Assets and Infrastructure Review Report) 2018 MISSION Act Veterans PACT Act Achieving Equity in the Treatment of Dual Eligible Beneficiaries Act (H.R. 7997) Bipartisan Safer Communities Act

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2022

Amendment

Elevance Health, Inc., formerly reported as Anthem, Inc. amended a lobbying report for representation of Anthem, Inc. in Q12022 on Oct. 20, 2022. Original Filing: 301418548.xml

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (individual mandate, cost sharing reduction subsidies, reinsurance transitional policies) ACA 1332 Waivers Individual market and exchange stabilization Prior authorization Hospital Consolidation Privacy and Healthcare Cybersecurity Social Determinants of Health (SDOH) Mental health and substance use, Parity and compliance issues; Surprise medical billing; No Surprises Act Price of prescription drugs Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing, Medicare Sequestration, ACA subsidies, COVID vaccines and testing, Consolidated Appropriations Act Behavioral Health Telehealth Short Term Limited Duration health plans Consolidated Appropriations Act, HR 133 Medical Loss Ratio; H.R. 3969 - To amend title XXVII of the Public Health Service Act to include activities to address social determinants of health in the calculation of medical loss ratios Federal Medical Assistance Percentages (FMAP) increase Special Enrollment Period CONNECT for Health Act Hospital Claims Form Issues H.R.5376 - Build Back Better Act KEEP Telehealth Options Act Opioid use disorders (OUD) and substance use disorders (SUD) treatment Agent/broker compensation disclosures under the Consolidated Appropriations Act. CAA regulation implementation Hospital Competition Act Medicaid eligibility Health Equity/Health Disparities Postal Service Reform Act of 2022; Postal Service Retiree Benefits Reform Defense Health Programs (FY2022 Budget and FY2023 Budget Request Veterans Health Care (U.S. Department of Veterans Affairs Assets and Infrastructure Review Report) Veterans Records Access (Access for Veterans to Records Act)

Agencies Lobbied

Type of Issue

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (individual mandate, cost sharing reduction subsidies, reinsurance transitional policies) ACA 1332 Waivers Individual market and exchange stabilization Prior authorization and Utilization Management, (H.R. 3107); Hospital Consolidation Privacy and Healthcare Cybersecurity Social Determinants of Health (SDOH) Mental health and substance use,42 CFR Part 2, Parity and compliance issues; Surprise medical billing; No Surprises Act Price of prescription drugs Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing, COVID-19 testing, vaccines, treatment, cost sharing Medical Loss Ratio; H.R. 3969 - To amend title XXVII of the Public Health Service Act to include activities to address social determinants of health in the calculation of medical loss ratios Federal Medical Assistance Percentages (FMAP) increase Short Term Limited Duration health plans Special Enrollment Period CONNECT for Health Act Hospital Claims Form Issues H.R.5376 - Build Back Better Act KEEP Telehealth Options Act Opioid use disorders (OUD) and substance use disorders (SUD) treatment Agent/broker compensation disclosures under the Consolidated Appropriations Act. CAA regulation implementation Hospital Competition Act Postal Service Reform Act of 2022; Postal Service Retiree Benefits Reform Defense Health Programs (FY2022 Budget and FY2023 Budget Request Veterans Health Care (U.S. Department of Veterans Affairs Assets and Infrastructure Review Report) Veterans Records Access (Access for Veterans to Records Act)

Agencies Lobbied

Type of Issue

Lobbying Issues

Medicare Advantage (risk adjustment, coding intensity, encounter data, dual-eligible members, star ratings, extreme and uncontrollable circumstances policy, normalization factors, stars contract consolidation, ESRD, audio-only telehealth H.R. 4074 -To amend title XVIII of the Social Security Act Medicare RAD-V Mental health and substance use (42 CFR Part 2) Medicaid (IMD Exclusion) Medicaid expansion Medicaid reform (block grants, per capita caps) Medicaid and CHIP reauthorization Medicaid actuarial soundness Long-term services and supports Social Determents of Health (SDOH) Medicare Part D prescription drug program and Medicare Part D coverage gap (donut hole) Opioid addiction issues and response (prescription drug monitoring programs) Medicaid medical loss ratio remittance Medicare Advantage Pilot Program in TRICARE Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing Direct and Indirect Remuneration (DIR) reforms in the FY 2023 Medicare Part D Notice H.R.6833 - Affordable Insulin Now Act Maternal health (Medicaid postpartum coverage extension, H.R.959 Black Maternal Health Momnibus Act of 2021) Helping MOMS Act of 2021 CMS Extreme & Uncontrollable Circumstances Policy Medicare Sequester (H.R.315, S.748) Medicare Audio-Only Telehealth (H.R.2166, S.150, H.R.3447) H.R. 4406, the Supporting Medicaid in the U.S. Territories Act, Continuing Resolution (CR)FY 2022 Medicaid Funding for Puerto Rico Medicare Advantage asks regarding the underfunding and disparity for Puerto Rico H.R.5376 - Build Back Better Act Medicaid eligibility Health Equity/Health Disparities HR1826 - Fairness in Medicare Part B Enrollment Act HR2217 - Territory Federal Matching Requirement Equity Act of 2021 HR1825 - A Bill to Remove the Matching Requirement for Medicate Part D Drugs.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2022

Q1 Report

In Q1, Anthem, Inc. had in-house lobbyists. The report was filed on April 20, 2022. Original Filing: 301370977.xml

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (individual mandate, cost sharing reduction subsidies, reinsurance transitional policies) ACA 1332 Waivers Individual market and exchange stabilization Prior authorization Hospital Consolidation Privacy and Healthcare Cybersecurity Social Determinants of Health (SDOH) Mental health and substance use, Parity and compliance issues; Surprise medical billing; No Surprises Act Price of prescription drugs Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing, Medicare Sequestration, ACA subsidies, COVID vaccines and testing, Consolidated Appropriations Act Behavioral Health Telehealth Short Term Limited Duration health plans Consolidated Appropriations Act, HR 133 Medical Loss Ratio; H.R. 3969 - To amend title XXVII of the Public Health Service Act to include activities to address social determinants of health in the calculation of medical loss ratios Federal Medical Assistance Percentages (FMAP) increase Special Enrollment Period CONNECT for Health Act Hospital Claims Form Issues H.R.5376 - Build Back Better Act KEEP Telehealth Options Act Opioid use disorders (OUD) and substance use disorders (SUD) treatment Agent/broker compensation disclosures under the Consolidated Appropriations Act. CAA regulation implementation Hospital Competition Act Medicaid eligibility Health Equity/Health Disparities Postal Service Reform Act of 2022; Postal Service Retiree Benefits Reform Defense Health Programs (FY2022 Budget and FY2023 Budget Request Veterans Health Care (U.S. Department of Veterans Affairs Assets and Infrastructure Review Report) Veterans Records Access (Access for Veterans to Records Act)

Agencies Lobbied

Type of Issue

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (individual mandate, cost sharing reduction subsidies, reinsurance transitional policies) ACA 1332 Waivers Individual market and exchange stabilization Prior authorization and Utilization Management, (H.R. 3107); Hospital Consolidation Privacy and Healthcare Cybersecurity Social Determinants of Health (SDOH) Mental health and substance use,42 CFR Part 2, Parity and compliance issues; Surprise medical billing; No Surprises Act Price of prescription drugs Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing, COVID-19 testing, vaccines, treatment, cost sharing Medical Loss Ratio; H.R. 3969 - To amend title XXVII of the Public Health Service Act to include activities to address social determinants of health in the calculation of medical loss ratios Federal Medical Assistance Percentages (FMAP) increase Short Term Limited Duration health plans Special Enrollment Period CONNECT for Health Act Hospital Claims Form Issues H.R.5376 - Build Back Better Act KEEP Telehealth Options Act Opioid use disorders (OUD) and substance use disorders (SUD) treatment Agent/broker compensation disclosures under the Consolidated Appropriations Act. CAA regulation implementation Hospital Competition Act Postal Service Reform Act of 2022; Postal Service Retiree Benefits Reform Defense Health Programs (FY2022 Budget and FY2023 Budget Request Veterans Health Care (U.S. Department of Veterans Affairs Assets and Infrastructure Review Report) Veterans Records Access (Access for Veterans to Records Act)

Agencies Lobbied

Type of Issue

Lobbying Issues

Medicare Advantage (risk adjustment, coding intensity, encounter data, dual-eligible members, star ratings, extreme and uncontrollable circumstances policy, normalization factors, stars contract consolidation, ESRD, audio-only telehealth H.R. 4074 -To amend title XVIII of the Social Security Act Medicare RAD-V Mental health and substance use (42 CFR Part 2) Medicaid (IMD Exclusion) Medicaid expansion Medicaid reform (block grants, per capita caps) Medicaid and CHIP reauthorization Medicaid actuarial soundness Long-term services and supports Social Determents of Health (SDOH) Medicare Part D prescription drug program and Medicare Part D coverage gap (donut hole) Opioid addiction issues and response (prescription drug monitoring programs) Medicaid medical loss ratio remittance Medicare Advantage Pilot Program in TRICARE Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing Direct and Indirect Remuneration (DIR) reforms in the FY 2023 Medicare Part D Notice H.R.6833 - Affordable Insulin Now Act Maternal health (Medicaid postpartum coverage extension, H.R.959 Black Maternal Health Momnibus Act of 2021) Helping MOMS Act of 2021 CMS Extreme & Uncontrollable Circumstances Policy Medicare Sequester (H.R.315, S.748) Medicare Audio-Only Telehealth (H.R.2166, S.150, H.R.3447) H.R. 4406, the Supporting Medicaid in the U.S. Territories Act, Continuing Resolution (CR)FY 2022 Medicaid Funding for Puerto Rico Medicare Advantage asks regarding the underfunding and disparity for Puerto Rico H.R.5376 - Build Back Better Act Medicaid eligibility Health Equity/Health Disparities HR1826 - Fairness in Medicare Part B Enrollment Act HR2217 - Territory Federal Matching Requirement Equity Act of 2021 HR1825 - A Bill to Remove the Matching Requirement for Medicate Part D Drugs.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2021

Q4 Report

In Q4, Anthem, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2022. Original Filing: 301336541.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2021

Q3 Report

In Q3, Anthem, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2021. Original Filing: 301312428.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2021

Q2 Report

In Q2, Anthem, Inc. had in-house lobbyists. The report was filed on July 20, 2021. Original Filing: 301289899.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2021

Q1 Report

In Q1, Anthem, Inc. had in-house lobbyists. The report was filed on April 20, 2021. Original Filing: 301265731.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Medicare Advantage (risk adjustment, coding intensity, encounter data, dual-eligible members, reauthorization of special need plans, star ratings, extreme and uncontrollable circumstances policy, normalization factors, stars contract consolidation, ESRD, audio-only telehealth Medicare RAD-V Mental health and substance use (42 CFR Part 2) Medicaid (IMD Exclusion) Medicaid expansion Medicaid reform (block grants, per capita caps) Medicaid and CHIP reauthorization Medicaid actuarial soundness Long-term services and supports Social Determents of Health (SDOH) Medicare Part D prescription drug program and Medicare Part D coverage gap (donut hole) Opioid addiction issues and response (prescription drug monitoring programs) Medicaid medical loss ratio remittance Medicare Advantage Pilot Program in TRICARE Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing Non Emergency Medical Transportation the Consolidated Appropriations Act (H.R. 133) Maternal health (Medicaid postpartum coverage extension, H.R.959 Black Maternal Health Momnibus Act of 2021)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2020

Q4 Report

In Q4, Anthem, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2021. Original Filing: 301241567.xml

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (individual mandate, cost sharing reduction subsidies, reinsurance transitional policies) Individual market and exchange stabilization Prior authorization and Utilization Management, (H.R. 3107); Hospital Consolidation Privacy and Healthcare Cybersecurity Digital, AI, and Blockchain Social Determinants of Health (SDOH) Mental health and substance use,42 CFR Part 2, Parity and compliance issues; H.R.7539 -Strengthening Behavioral Health Parity Act and the Consolidated Appropriations Act (H.R. 133) Surprise medical billing; Lower Health Care Cost Act of 2019 (S. 1895), and No Surprises Act (H.R. 3630); and the Consolidated Appropriations Act (H.R. 133) Price of prescription drugs Commercial Risk adjustment data validation (RADV) Senate HELP Committee Lower Health Care Costs Act Senate Finance Committee Prescription Drug Pricing Reduction Act; (H.R. 3) Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing, Lower Health Care Cost Act of 2019 (S. 1895) and the Consolidated Appropriations Act (H.R. 133) COVID-19 legislation (Phase I, II, III and other); Families First Coronavirus Response Act (H.R. 6201); Coronavirus Aid, Relief, and Economic Security (CARES) Act; The Heroes Act (H.R. 925 and 6800); HEALS Act (S. 1624); the Consolidated Appropriations Act (H.R. 133); SEPs; Risk Mitigation and Excess Loss; COBRA; Testing and Coverage Mandates Federal Medical Assistance Percentages (FMAP) increase McCarran-Ferguson Act repeal; the Competitive Health Insurance Reform Act of 2020 (S. 350) and Competitive Health Insurance Reform Act of 2019 (H.R. 1418)

Agencies Lobbied

Type of Issue

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (individual mandate, cost sharing reduction subsidies, reinsurance transitional policies) Individual market and exchange stabilization Prior authorization and Utilization Management, (H.R. 3107); Hospital Consolidation Privacy and Healthcare Cybersecurity Digital, AI, and Blockchain Social Determinants of Health (SDOH) Mental health and substance use,42 CFR Part 2, Parity and compliance issues; H.R.7539 -Strengthening Behavioral Health Parity Act and the Consolidated Appropriations Act (H.R. 133) Surprise medical billing; Lower Health Care Cost Act of 2019 (S. 1895), and No Surprises Act (H.R. 3630); and the Consolidated Appropriations Act (H.R. 133) Price of prescription drugs Commercial Risk adjustment data validation (RADV) Senate HELP Committee Lower Health Care Costs Act Senate Finance Committee Prescription Drug Pricing Reduction Act; (H.R. 3) Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing, Lower Health Care Cost Act of 2019 (S. 1895) and the Consolidated Appropriations Act (H.R. 133) COVID-19 legislation (Phase I, II, III and other); Families First Coronavirus Response Act (H.R. 6201); Coronavirus Aid, Relief, and Economic Security (CARES) Act; The Heroes Act (H.R. 925 and 6800); HEALS Act (S. 1624); the Consolidated Appropriations Act (H.R. 133); SEPs; Risk Mitigation and Excess Loss; COBRA; Testing and Coverage Mandates Federal Medical Assistance Percentages (FMAP) increase McCarran-Ferguson Act repeal; the Competitive Health Insurance Reform Act of 2020 (S. 350) and Competitive Health Insurance Reform Act of 2019 (H.R. 1418)

Agencies Lobbied

Type of Issue

Lobbying Issues

Medicare Advantage (risk adjustment, coding intensity, encounter data, dual-eligible members, reauthorization of special need plans, star ratings, extreme and uncontrollable circumstances policy, normalization factors, stars contract consolidation, ESRD, audio-only telehealth) Medicare RAD-V Mental health and substance use (42 CFR Part 2) Medicaid managed care (MIND Act) (H.R. 6926) (IMD Exclusion) Medicaid expansion Medicaid reform (block grants, per capita caps) Medicaid and CHIP reauthorization Medicaid actuarial soundness Long-term services and supports Social Determents of Health (SDOH) Medicare Part D prescription drug program and Medicare Part D coverage gap (donut hole) Opioid addiction issues and response (prescription drug monitoring programs) Medicaid medical loss ratio remittance Medicare Advantage Pilot Program in TRICARE Maternal Health Quality Improvement Act (H.R. 4995) Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing Non Emergency Medical Transportation (The Protecting Patients Transportation to Care Act)(S.2846); the Consolidated Appropriations Act (H.R. 133) Medicaid maternal health coverage expansion (H.R.6800)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2020

Q3 Report

In Q3, Anthem, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2020. Original Filing: 301219392.xml

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (reconciliation, individual mandate, cost sharing reduction subsidies, reinsurance transitional policies) Individual market and exchange stabilization Prior authorization and Utilization Management, (H.R. 3107); Uterine Fibroids Coverage Hospital Consolidation Privacy and Healthcare Cybersecurity Digital, AI, and Blockchain Social Determinants of Health (SDOH) Mental health and substance use,42 CFR Part 2, Parity and compliance issues Surprise medical billing; Lower Health Care Cost Act of 2019 (S. 1895), and No Surprises Act (H.R. 3630) Price of prescription drugs Commercial Risk adjustment data validation (RADV) Senate HELP Committee Lower Health Care Costs Act Senate Finance Committee Prescription Drug Pricing Reduction Act; (H.R. 3) Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing, Lower Health Care Cost Act of 2019 (S. 1895) COVID-19 legislation (Phase I, II, III and other); Families First Coronavirus Response Act (H.R. 6201); Coronavirus Aid, Relief, and Economic Security (CARES) Act; The Heroes Act (H.R. 6800); HEALS Act (S. 1624); SEPs; Risk Mitigation and Excess Loss; COBRA; Testing and Coverage Mandates Federal Medical Assistance Percentages (FMAP) increase

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Medicare Advantage (risk adjustment, coding intensity, encounter data, dual-eligible members, reauthorization of special need plans, star ratings, extreme and uncontrollable circumstances policy, normalization factors, stars contract consolidation, ESRD, audio-only telehealth) Medicare RAD-V Mental health and substance use (42 CFR Part 2) Medicaid managed care (MIND Act) (H.R. 6926) (IMD Exclusion) Medicaid expansion Medicaid reform (block grants, per capita caps) Medicaid and CHIP reauthorization Medicaid actuarial soundness Long-term services and supports Social Determents of Health (SDOH) Medicare Part D prescription drug program and Medicare Part D coverage gap (donut hole) Opioid addiction issues and response (prescription drug monitoring programs) Medicaid medical loss ratio remittance Medicare Advantage Pilot Program in TRICARE Maternal Health Quality Improvement Act (H.R. 4995) Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing Non Emergency Medical Transportation (The Protecting Patients Transportation to Care Act)(S.2846) Medicaid maternal health coverage expansion (H.R.6800)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2020

Q2 Report

In Q2, Anthem, Inc. had in-house lobbyists. The report was filed on July 20, 2020. Original Filing: 301199664.xml

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (reconciliation, individual mandate, cost sharing reduction subsidies, reinsurance transitional policies) Individual market and exchange stabilization Prior authorization, (H.R. 3107) Hospital Consolidation Privacy and Healthcare Cybersecurity Social Determinants of Health (SDOH) Mental health and substance use,42 CFR Part 2, Parity and compliance issues Surprise medical billing; Lower Health Care Cost Act of 2019 (S. 1895), and No Surprises Act (H.R. 3630) Price of prescription drugs Commercial Risk adjustment data validation (RADV) Senate HELP Committee Lower Health Care Costs Act Senate Finance Committee Prescription Drug Pricing Reduction Act; (H.R. 3) Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing, Lower Health Care Cost Act of 2019 (S. 1895) COVID-19 legislation (Phase I, II, III and other); Commercial paper market stability; Families First Coronavirus Response Act (H.R. 6201); Coronavirus Aid, Relief, and Economic Security (CARES) Act; SEPs; Risk Mitigation and Excess Loss; COBRA; Coverage Mandates Federal Medical Assistance Percentages (FMAP) increase

Agencies Lobbied

Type of Issue

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (reconciliation, individual mandate, cost sharing reduction subsidies, reinsurance transitional policies) Individual market and exchange stabilization Prior authorization, (H.R. 3107) Hospital Consolidation Privacy and Healthcare Cybersecurity Social Determinants of Health (SDOH) Mental health and substance use,42 CFR Part 2, Parity and compliance issues Surprise medical billing; Lower Health Care Cost Act of 2019 (S. 1895), and No Surprises Act (H.R. 3630) Price of prescription drugs Commercial Risk adjustment data validation (RADV) Senate HELP Committee Lower Health Care Costs Act Senate Finance Committee Prescription Drug Pricing Reduction Act; (H.R. 3) Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing, Lower Health Care Cost Act of 2019 (S. 1895) COVID-19 legislation (Phase I, II, III and other); Commercial paper market stability; Families First Coronavirus Response Act (H.R. 6201); Coronavirus Aid, Relief, and Economic Security (CARES) Act; SEPs; Risk Mitigation and Excess Loss; COBRA; Coverage Mandates Federal Medical Assistance Percentages (FMAP) increase

Agencies Lobbied

Type of Issue

Lobbying Issues

Medicare Advantage (risk adjustment, coding intensity, encounter data, dual-eligible members, reauthorization of special need plans, star ratings, normalization factors, stars contract consolidation, ESRD, audio-only telehealth) Medicare RAD-V Mental health and substance use (42 CFR Part 2) Medicaid managed care (MIND Act) (H.R. 6926) (IMD Exclusion) Medicaid expansion Medicaid reform (block grants, per capita caps) Medicaid and CHIP reauthorization Medicaid actuarial soundness Long-term services and supports Social Determents of Health (SDOH) Medicare Part D prescription drug program and Medicare Part D coverage gap (donut hole) Medicare Part D crosswalk policy Opioid addiction issues and response (prescription drug monitoring programs) Medicaid medical loss ratio remittance Medicaid non-emergency medical transportation Medicare Advantage Pilot Program in TRICARE Maternal Health Quality Improvement Act (H.R. 4995) Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing, Drug Price Transparency in Medicaid Act of 2019 (H.R. 5281) Non Emergency Medical Transportation (The Protecting Patients Transportation to Care Act)(S.2846) Medicaid maternal health coverage expansion (H.R.6800)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2020

Q1 Report

In Q1, Anthem, Inc. had in-house lobbyists. The report was filed on April 20, 2020. Original Filing: 301176220.xml

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (reconciliation, individual mandate, cost sharing reduction subsidies, reinsurance transitional policies) Individual market and exchange stabilization Prior authorization, (H.R. 3107) Hospital Consolidation Privacy and Healthcare Cybersecurity Social Determinants of Health (SDOH) Association health plans Mental health and substance use,42 CFR Part 2, Parity and compliance issues Surprise medical billing; Lower Health Care Cost Act of 2019 (S. 1895), and No Surprises Act (H.R. 3630) Price of prescription drugs Commercial Risk adjustment data validation (RADV) Senate HELP Committee Lower Health Care Costs Act Senate Finance Committee Prescription Drug Pricing Reduction Act; HR 3 Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing, Lower Health Care Cost Act of 2019 (S. 1895) COVID-19 legislation (Phase I, II, III and other); Commercial paper market stability; Families First Coronavirus Response Act (HR 6201); Coronavirus Aid, Relief, and Economic Security (CARES) Act; SEPs; Risk Mitigation and Excess Loss; COBRA; Coverage Mandates

Agencies Lobbied

Type of Issue

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (reconciliation, individual mandate, cost sharing reduction subsidies, reinsurance transitional policies) Individual market and exchange stabilization Prior authorization, (H.R. 3107) Hospital Consolidation Privacy and Healthcare Cybersecurity Social Determinants of Health (SDOH) Association health plans Mental health and substance use,42 CFR Part 2, Parity and compliance issues Surprise medical billing; Lower Health Care Cost Act of 2019 (S. 1895), and No Surprises Act (H.R. 3630) Price of prescription drugs Commercial Risk adjustment data validation (RADV) Senate HELP Committee Lower Health Care Costs Act Senate Finance Committee Prescription Drug Pricing Reduction Act; HR 3 Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing, Lower Health Care Cost Act of 2019 (S. 1895) COVID-19 legislation (Phase I, II, III and other); Commercial paper market stability; Families First Coronavirus Response Act (HR 6201); Coronavirus Aid, Relief, and Economic Security (CARES) Act; SEPs; Risk Mitigation and Excess Loss; COBRA; Coverage Mandates

Agencies Lobbied

Type of Issue

Lobbying Issues

Medicare Advantage (risk adjustment, coding intensity, encounter data, dual-eligible members, reauthorization of special need plans, star ratings, normalization factors, stars contract consolidation) Medicare RAD-V Mental health and substance use (42 CFR Part 2) Medicaid managed care Medicaid expansion Medicaid reform (block grants, per capita caps) Medicaid and CHIP reauthorization Medicaid actuarial soundness Long-term services and supports Social Determents of Health (SDOH) Medicare Part D prescription drug program and Medicare Part D coverage gap (donut hole) Medicare Part D crosswalk policy Opioid addiction issues and response (prescription drug monitoring programs) Medicaid medical loss ratio remittance Medicaid non-emergency medical transportation Medicare Advantage Pilot Program in TRICARE Maternal Health Quality Improvement Act (H.R. 4995) Medicaid Maternal Health Outcomes and Coverage; Helping Medicaid Offer Maternity Services (MOMS) Act of 2019 (H.R. 4996) Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing, Drug Price Transparency in Medicaid Act of 2019 (H.R. 5281) Telehealth

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2019

Q4 Report

In Q4, Anthem, Inc. had in-house lobbyists. The report was filed on Jan. 21, 2020. Original Filing: 301127241.xml

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (reconciliation, individual mandate, cost sharing reduction subsidies, reinsurance transitional policies) Individual market and exchange stabilization Prior authorization Hospital Consolidation Privacy and Healthcare Cybersecurity Social Determinants of Health (SDOH) Association health plans Mental health and substance use,42 CFR Part 2, Parity and compliance issues Surprise medical billing; Lower Health Care Cost Act of 2019 (S. 1895), and No Surprises Act (H.R. 3630) Price of prescription drugs Medical Loss Ratios Commercial Risk adjustment data validation (RADV) Senate HELP Committee Lower Health Care Costs Act Senate Finance Committee Prescription Drug Pricing Reduction Act; HR 3 Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing, Lower Health Care Cost Act of 2019 (S. 1895) Spending Agreement to fund Federal Government for 2020 fiscal year; National Security minibus (H.R. 1158) and the Domestic Priorities and International Assistance minibus of appropriations bills (H.R.1865)

Agencies Lobbied

Type of Issue

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (reconciliation, individual mandate, cost sharing reduction subsidies, reinsurance transitional policies) Individual market and exchange stabilization Prior authorization Hospital Consolidation Privacy and Healthcare Cybersecurity Social Determinants of Health (SDOH) Association health plans Mental health and substance use,42 CFR Part 2, Parity and compliance issues Surprise medical billing; Lower Health Care Cost Act of 2019 (S. 1895), and No Surprises Act (H.R. 3630) Price of prescription drugs Medical Loss Ratios Commercial Risk adjustment data validation (RADV) Senate HELP Committee Lower Health Care Costs Act Senate Finance Committee Prescription Drug Pricing Reduction Act; HR 3 Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing, Lower Health Care Cost Act of 2019 (S. 1895) Spending Agreement to fund Federal Government for 2020 fiscal year; National Security minibus (H.R. 1158) and the Domestic Priorities and International Assistance minibus of appropriations bills (H.R.1865)

Agencies Lobbied

Type of Issue

Lobbying Issues

Medicare Advantage (risk adjustment, coding intensity, encounter data, dual-eligible members, reauthorization of special need plans, star ratings, normalization factors, stars contract consolidation) Medicare RAD-V Mental health and substance use (42 CFR Part 2) Medicaid managed care Medicaid expansion Medicaid reform (block grants, per capita caps) Medicaid and CHIP reauthorization Medicaid actuarial soundness Long-term services and supports Social Determents of Health (SDOH) Medicare Part D prescription drug program and Medicare Part D coverage gap (donut hole) Medicare Part D crosswalk policy Opioid addiction issues and response (prescription drug monitoring programs) Medicaid medical loss ratio remittance Medicaid non-emergency medical transportation Medicare Advantage Pilot Program in TRICARE Kentucky Medicaid RFP Decision Maternal Health Quality Improvement Act (H.R. 4995) Medicaid Maternal Health Outcomes and Coverage; Helping Medicaid Offer Maternity Services (MOMS) Act of 2019 (H.R. 4996) Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing, Drug Price Transparency in Medicaid Act of 2019 (H.R. 5281)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2019

Q3 Report

In Q3, Anthem, Inc. had in-house lobbyists. The report was filed on Oct. 21, 2019. Original Filing: 301076301.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Medicare Advantage (risk adjustment, coding intensity, encounter data, dual-eligible members, reauthorization of special need plans, star ratings, normalization factors, stars contract consolidation) Medicare RAD-V Mental health and substance use (42 CFR Part 2) Medicaid managed care Medicaid expansion Medicaid reform (block grants, per capita caps) Medicaid and CHIP reauthorization Medicaid actuarial soundness Long-term services and supports Social Determents of Health (SDOH) Medicare Part D prescription drug program and Medicare Part D coverage gap (donut hole) Removal of safe harbor protections for rebates involving prescription drugs and the creation of new safe harbor protection for certain point-of-sale reductions on price on prescription drugs and certain Pharmacy Benefit Manager (PBM) service fees Medicare Part D crosswalk policy Opioid addiction issues and response (prescription drug monitoring programs) Medicaid medical loss ratio remittance Medicaid non-emergency medical transportation Medicare Advantage Pilot Program in TRICARE

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2019

Q2 Report

In Q2, Anthem, Inc. had in-house lobbyists. The report was filed on July 22, 2019. Original Filing: 301057612.xml

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (reconciliation, individual mandate, cost sharing reduction subsidies, reinsurance transitional policies) Individual market and exchange stabilization Commercial Risk adjustment data validation (RADV) Strengthening Health Care and Lowering Prescription Drug Costs Act (H.R. 987) Patient Affordability Value and Efficiency Act (PAVE Act) Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act of 2019 (S. 340 and H.R. 965) Mental health and substance use,42 CFR Part 2, Parity and compliance issues Surprise medical billing; Lower Health Care Cost Act of 2019 (S. 1895), and No Surprises Act (H.R. 3630) Telehealth Price of prescription drugs Prior authorization Hospital Consolidation (The Hospital Competition Act of 2018, H.R. 7084) Social Determinants of Health (SDOH) Privacy and Healthcare Cybersecurity Health information exchange and interoperability Association health plans ACA third party payments Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing, Lower Health Care Cost Act of 2019 (S. 1895) Readiness for Elders and Americans with Disabilities Inclusion (READI) for Disaster Act (S. 3679)

Agencies Lobbied

Type of Issue

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (reconciliation, individual mandate, cost sharing reduction subsidies, reinsurance transitional policies) Individual market and exchange stabilization Commercial Risk adjustment data validation (RADV) Strengthening Health Care and Lowering Prescription Drug Costs Act (H.R. 987) Patient Affordability Value and Efficiency Act (PAVE Act) Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act of 2019 (S. 340 and H.R. 965) Mental health and substance use,42 CFR Part 2, Parity and compliance issues Surprise medical billing; Lower Health Care Cost Act of 2019 (S. 1895), and No Surprises Act (H.R. 3630) Telehealth Price of prescription drugs Prior authorization Hospital Consolidation (The Hospital Competition Act of 2018, H.R. 7084) Social Determinants of Health (SDOH) Privacy and Healthcare Cybersecurity Health information exchange and interoperability Association health plans ACA third party payments Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing, Lower Health Care Cost Act of 2019 (S. 1895) Readiness for Elders and Americans with Disabilities Inclusion (READI) for Disaster Act (S. 3679

Agencies Lobbied

Type of Issue

Lobbying Issues

Medicare Advantage (risk adjustment, coding intensity, encounter data, dual-eligible members, reauthorization of special need plans, star ratings, normalization factors, stars contract consolidation) Medicare expansion Mental health and substance use (42 CFR Part 2) Medicaid managed care Medicaid expansion Medicaid reform (block grants, per capita caps) Medicaid and CHIP reauthorization Medicaid actuarial soundness Long-term services and supports Social Determents of Health (SDOH) Medicare Part D prescription drug program and Medicare Part D coverage gap (donut hole) Removal of safe harbor protections for rebates involving prescription drugs and the creation of new safe harbor protection for certain point-of-sale reductions on price on prescription drugs and certain Pharmacy Benefit Manager (PBM) service fees Medicare Part D crosswalk policy Opioid addiction issues and response (prescription drug monitoring programs) Medicaid medical loss ratio remittance Medicaid non-emergency medical transportation ACE Kids Act of 2019 and the Medicaid Services Investment and Accountability Act of 2019 (S. 317, H.R. 1226, and H.R. 1839) Medicare Advantage Pilot Program in TRICARE

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2019

Q1 Report

In Q1, Anthem, Inc. had in-house lobbyists. The report was filed on April 22, 2019. Original Filing: 301036975.xml

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (reconciliation, individual mandate, cost sharing reduction subsidies, reinsurance transitional policies) Individual market and exchange stabilization State Health Care Premium Reduction Act (H.R. 1425), Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act (H.R. 1386), and State Allowance for a Variety of Exchanges (SAVE) Act (H.R. 1385) Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act of 2019 (S. 340 and H.R. 965) Mental health and substance use (42 CFR Part 2) Surprise Medical Billing Telehealth Price of prescription drugs Opioid addiction issues Prior authorization Hospital Consolidation (The Hospital Competition Act of 2018, H.R. 7084) Social Determinants of Health (SDOH) Privacy and Healthcare Cybersecurity Health information exchange and interoperability

Agencies Lobbied

Type of Issue

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (reconciliation, individual mandate, cost sharing reduction subsidies, reinsurance transitional policies) Individual market and exchange stabilization State Health Care Premium Reduction Act (H.R. 1425), Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act (H.R. 1386), and State Allowance for a Variety of Exchanges (SAVE) Act (H.R. 1385) Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act of 2019 (S. 340 and H.R. 965) Mental health and substance use (42 CFR Part 2) Surprise Medical Billing Telehealth Price of prescription drugs Opioid addiction issues Prior authorization Hospital Consolidation (The Hospital Competition Act of 2018, H.R. 7084) Social Determinants of Health (SDOH) Privacy and Healthcare Cybersecurity Health information exchange and interoperability

Agencies Lobbied

Type of Issue

Lobbying Issues

Medicare Advantage (risk adjustment, coding intensity, encounter data, dual-eligible members, reauthorization of special need plans, star ratings, normalization factors, stars contract consolidation) Medicare expansion Mental health and substance use (42 CFR Part 2) Medicaid managed care Medicaid expansion Medicaid reform (block grants, per capita caps) Medicaid and CHIP reauthorization Medicaid actuarial soundness Long-term services and supports Social Determents of Health (SDOH) Medicare Part D prescription drug program and Medicare Part D coverage gap (donut hole) Removal of safe harbor protections for rebates involving prescription drugs and the creation of new safe harbor protection for certain point-of-sale reductions on price on prescription drugs and certain Pharmacy Benefit Manager (PBM) service fees Opioid addiction issues and response (prescription drug monitoring programs) Medicaid medical loss ratio remittance Medicaid non-emergency medical transportation ACE Kids Act of 2019 and the Medicaid Services Investment and Accountability Act of 2019 (S. 317, H.R. 1226, and H.R. 1839) Medicare Advantage Pilot Program in TRICARE

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2018

Q4 Report

In Q4, Anthem, Inc. had in-house lobbyists. The report was filed on Jan. 22, 2019. Original Filing: 301016372.xml

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (reconciliation, individual mandate, cost sharing reduction subsidies, reinsurance transitional policies) The Bipartisan Budget Act of 2018 (H.R. 1892) Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act of 2017 (S. 974 and H.R. 2212) Overdose Prevention and Patient Safety Act (H.R. 3545 and H.R. 6082) Jessies Law (H.R. 5009) Mental health and substance use (42 CFR Part 2) Individual market and exchange stabilization Association health plans Short Term Limited Duration Plans Out of network billing (FAA Reauthorization Act of 2018, H.R. 302) ACA third party payments Telehealth Price of prescription drugs Opioid addiction issues and response (prescription drug monitoring programs) Prior authorization SUPPORT for Patients and Communities Act (H.R. 6) Veterans health care Task Force on the Impact of Affordable Housing Crisis Act of 2018 (S. 3231) Readiness for Elders and Americans with Disabilities Inclusion (READI) for Disaster Act (S. 3679)

Agencies Lobbied

Type of Issue

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (reconciliation, individual mandate, cost sharing reduction subsidies, reinsurance transitional policies) The Bipartisan Budget Act of 2018 (H.R. 1892) Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act of 2017 (S. 974 and H.R. 2212) Overdose Prevention and Patient Safety Act (H.R. 3545 and H.R. 6082) Jessies Law (H.R. 5009) Mental health and substance use (42 CFR Part 2) Individual market and exchange stabilization Association health plans Short Term Limited Duration Plans Out of network billing (FAA Reauthorization Act of 2018, H.R. 302) ACA third party payments Telehealth Price of prescription drugs Opioid addiction issues and response (prescription drug monitoring programs) Prior authorization SUPPORT for Patients and Communities Act (H.R. 6) Veterans health care Task Force on the Impact of Affordable Housing Crisis Act of 2018 (S. 3231) Readiness for Elders and Americans with Disabilities Inclusion (READI) for Disaster Act (S. 3679)

Agencies Lobbied

Type of Issue

Lobbying Issues

Medicare Advantage (risk adjustment, coding intensity, encounter data, dual-eligible members, reauthorization of special need plans, star ratings, normalization factors, stars contract consolidation) Mental health and substance use (42 CFR Part 2) The Bipartisan Budget Act of 2018 (H.R. 1892) Medicaid managed care Medicaid expansion Medicaid reform (block grants, per capita caps) Medicaid and CHIP reauthorization Long-term services and supports Medicare Part D prescription drug program and Medicare Part D coverage gap (donut hole) Clinical decision support Opioid addiction issues and response (prescription drug monitoring programs) Medicaid medical loss ratio remittance and IMD exclusion for inpatient Medicaid payments Medicaid non-emergency medical transportation ACE Kids Act (H.R. 3325) Dialysis Patient Access to Integrated-care, Empowerment, Nephrologists, Treatment, and Services (PATIENTS) Demonstration Act of 2017 (H.R. 4143) Improving Medicaid Programs and Opportunities for Eligible Beneficiaries (IMPROVE) Act (H.R. 7217)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2018

Q3 Report

In Q3, Anthem, Inc. had in-house lobbyists. The report was filed on Oct. 22, 2018. Original Filing: 300997685.xml

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment, transitional policies) ACA reform (reconciliation, individual mandate, cost sharing reduction subsidies, reinsurance) ACA enrollment The Bipartisan Budget Act of 2018 (H.R. 1892) Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act of 2017 (S. 974 and H.R. 2212) Overdose Prevention and Patient Safety Act (H.R. 3545 and H.R. 6082) Jessies Law (H.R. 5009) Mental health and substance use (42 CFR Part 2) Individual market and exchange stabilization Association health plans Short Term Limited Duration Plans Out of network billing (FAA Reauthorization Act of 2018, H.R. 302) ACA third party payments Telehealth Price of prescription drugs Opioid addiction issues and response (prescription drug monitoring programs) H.R. 6, SUPPORT for Patients and Communities Act

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Medicare Advantage (risk adjustment, coding intensity, encounter data, dual-eligible members, reauthorization of special need plans, star ratings, normalization factors, stars contract consolidation) Mental health and substance use (42 CFR Part 2) The Bipartisan Budget Act of 2018 (H.R. 1892) Medicaid managed care Medicaid expansion Medicaid reform (block grants, per capita caps) Medicaid and CHIP reauthorization Long-term services and supports Medicare Part D prescription drug program and Medicare Part D coverage gap (donut hole) Clinical decision support Opioid addiction issues and response (prescription drug monitoring programs) Section 701 of H.R. 5515, the National Defense Authorization Act for Fiscal Year 2019 H.R. 6042, a bill to delay the reduction in Federal medical assistance percentage for Medicaid personal care services furnished without an electronic visit verification system Medicaid medical loss ratio H.R. 6, SUPPORT for Patients and Communities Act ACE Kids Act (H.R. 3325)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2018

Q2 Report

In Q2, Anthem, Inc. had in-house lobbyists. The report was filed on July 20, 2018. Original Filing: 300977129.xml

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment, transitional policies) ACA reform (reconciliation, individual mandate, cost sharing reduction subsidies, reinsurance) The Bipartisan Budget Act of 2018 (H.R. 1892) Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act of 2017 (S. 974 and H.R. 2212) Overdose Prevention and Patient Safety Act (H.R. 3545 and H.R. 6082) Jessies Law (H.R. 5009) Mental health and substance use (42 CFR Part 2) Individual market and exchange stabilization Association health plans Short Term Limited Duration Plans Out of network billing ACA third party payments Telehealth Price of prescription drugs Opioid addiction issues and response (prescription drug monitoring programs) H.R. 6, SUPPORT for Patients and Communities Act

Agencies Lobbied

Type of Issue

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment, transitional policies) ACA reform (reconciliation, individual mandate, cost sharing reduction subsidies, reinsurance) The Bipartisan Budget Act of 2018 (H.R. 1892) Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act of 2017 (S. 974 and H.R. 2212) Overdose Prevention and Patient Safety Act (H.R. 3545 and H.R. 6082) Jessies Law (H.R. 5009) Mental health and substance use (42 CFR Part 2) Individual market and exchange stabilization Association health plans Short Term Limited Duration Plans Out of network billing ACA third party payments Telehealth Price of prescription drugs Opioid addiction issues and response (prescription drug monitoring programs) H.R. 6, SUPPORT for Patients and Communities Act

Agencies Lobbied

Type of Issue

Lobbying Issues

Medicare Advantage (risk adjustment, coding intensity, encounter data, dual-eligible members, reauthorization of special need plans, star ratings, normalization factors, stars contract consolidation) Mental health and substance use (42 CFR Part 2) The Bipartisan Budget Act of 2018 (H.R. 1892) Medicaid managed care Medicaid expansion Medicaid reform (block grants, per capita caps) Medicaid and CHIP reauthorization Medicaid actuarial soundness Long-term services and supports Medicare Part D prescription drug program and Medicare Part D coverage gap (donut hole) Clinical decision support Medicare fraud, waste, and abuse Opioid addiction issues and response (prescription drug monitoring programs) Section 701 of H.R. 5515, the National Defense Authorization Act for Fiscal Year 2019 H.R. 6042, a bill to delay the reduction in Federal medical assistance percentage for Medicaid personal care services furnished without an electronic visit verification system Medicaid medical loss ratio H.R. 6, SUPPORT for Patients and Communities Act Telehealth H.R. 5773, Preventing Addiction for Susceptible Seniors (PASS) Act of 2018 H.R. 5797, Individuals in Medicaid Deserve Care that is Appropriate and Responsible in its Execution Act

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2018

Q1 Report

In Q1, Anthem, Inc. had in-house lobbyists. The report was filed on April 20, 2018. Original Filing: 300956884.xml

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment, transitional policies) ACA reform (reconciliation, individual mandate, cost sharing reduction subsidies, reinsurance) The Bipartisan Budget Act of 2018 (H.R. 1892) Bipartisan Health Care Stabilization Act of 2018 (Amendment to S. 1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018) Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act of 2017 (S. 974 and H.R. 2212) Overdose Prevention and Patient Safety Act (H.R. 3545) Jessies Law (H.R. 5009) Prescription Drug Monitoring Act of 2017 (S. 778) CARA 2.0 Act of 2018 (S. 2456) Consolidated Appropriations Act, 2018 (H.R. 1625) Lower Premiums Through Reinsurance Act (S. 1835) Mental health and substance use (42 CFR Part 2) Individual market and exchange stabilization Association health plans Short Term Limited Duration Plans Out of network billing ACA third party payments Telehealth Price of prescription drugs Opioid addiction issues and response (prescription drug monitoring programs)

Agencies Lobbied

Type of Issue

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment, transitional policies) ACA reform (reconciliation, individual mandate, cost sharing reduction subsidies, reinsurance) The Bipartisan Budget Act of 2018 (H.R. 1892) Bipartisan Health Care Stabilization Act of 2018 (Amendment to S. 1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018) Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act of 2017 (S. 974 and H.R. 2212) Overdose Prevention and Patient Safety Act (H.R. 3545) Jessies Law (H.R. 5009) Prescription Drug Monitoring Act of 2017 (S. 778) CARA 2.0 Act of 2018 (S. 2456) Consolidated Appropriations Act, 2018 (H.R. 1625) Lower Premiums Through Reinsurance Act (S. 1835) Mental health and substance use (42 CFR Part 2) Individual market and exchange stabilization Association health plans Short Term Limited Duration Plans Out of network billing ACA third party payments Telehealth Price of prescription drugs Opioid addiction issues and response (prescription drug monitoring programs)

Agencies Lobbied

Type of Issue

Lobbying Issues

Medicare Advantage (risk adjustment, coding intensity, encounter data, dual-eligible members, reauthorization of special need plans (including H.R. 3168), star ratings, normalization factors, stars contract consolidation) Creating High-Quality Results and Outcomes Necessary to Improve Chronic Care Act of 2017 (S. 870 and H.R. 4579) Mental health and substance use (42 CFR Part 2) The Bipartisan Budget Act of 2018 (H.R. 1892) The Connect for Health Act of 2017 (H.R.2556 and S.1016) Medicaid managed care Medicaid expansion Medicaid reform (block grants, per capita caps) Medicaid and CHIP reauthorization Medicaid actuarial soundness Long-term services and supports Medicare Part D Clinical decision support Medicare fraud, waste, and abuse Opioid addiction issues and response (prescription drug monitoring programs)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2017

Q4 Report

In Q4, Anthem, Inc. had in-house lobbyists. The report was filed on Jan. 22, 2018. Original Filing: 300936462.xml

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment, transitional policies) ACA reform (reconciliation, individual mandate, cost sharing reduction subsidies) The American Health Care Act and related amendments (H.R. 1628 and H. Res. 154) The Better Care Reconciliation Act of 2017 The Health Care Options for All Act (S. 1201) The Individual Health Insurance Marketplace Improvement Act (S. 1354) The Marketplace Certainty Act (S. 1462) Lower Premiums Through Reinsurance Act (S. 1835) Patient Freedom Act of 2017 (S. 191) Making further supplemental appropriations for the fiscal year ending September 30, 2018, for disaster assistance for Hurricanes Harvey, Irma, and Maria, and calendar year 2017 wildfires, and for other purposes (H.R. 4667) Championing Healthy Kids Act (H.R. 3922) Keep Kids' Insurance Dependable and Secure Act of 2017 (S. 1827) Mental health and substance use (42 CFR Part 2) 2019 Notice of Benefit and Payment Parameters proposed rule Individual market and exchange stabilization Association health plans Out of network billing ACA third party payments Telehealth Price of prescription drugs Opioid addiction issues and response (prescription drug monitoring programs)

Agencies Lobbied

Type of Issue

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment, transitional policies) ACA reform (reconciliation, individual mandate, cost sharing reduction subsidies) The American Health Care Act and related amendments (H.R. 1628 and H. Res. 154) The Better Care Reconciliation Act of 2017 The Health Care Options for All Act (S. 1201) The Individual Health Insurance Marketplace Improvement Act (S. 1354) The Marketplace Certainty Act (S. 1462) Lower Premiums Through Reinsurance Act (S. 1835) Patient Freedom Act of 2017 (S. 191) Making further supplemental appropriations for the fiscal year ending September 30, 2018, for disaster assistance for Hurricanes Harvey, Irma, and Maria, and calendar year 2017 wildfires, and for other purposes (H.R. 4667) Championing Healthy Kids Act (H.R. 3922) Keep Kids' Insurance Dependable and Secure Act of 2017 (S. 1827) Mental health and substance use (42 CFR Part 2) 2019 Notice of Benefit and Payment Parameters proposed rule Individual market and exchange stabilization Association health plans Out of network billing ACA third party payments Telehealth Price of prescription drugs Opioid addiction issues and response (prescription drug monitoring programs)

Agencies Lobbied

Type of Issue

Lobbying Issues

Medicare Advantage (risk adjustment, coding intensity, encounter data, dual-eligible members, reauthorization of special need plans (including H.R. 3168), star ratings, normalization factors) The American Health Care Act and related amendments (H.R. 1628 and H. Res. 154) The Better Care Reconciliation Act of 2017 Creating High-Quality Results and Outcomes Necessary to Improve Chronic Care Act of 2017 (S. 870) The CONNECT for Health Act of 2017 (H.R. 2556, S. 1016) Expanding access to telehealth in Medicare (H.R. 3727 and H.R. 3482) Medicaid Accountability and Care Act of 2017 (S. 520) To amend title XVIII of the Social Security Act to expand access to home dialysis therapy (H.R. 3164) Medicaid managed care Medicaid expansion Medicaid reform (block grants, per capita caps) Medicaid and CHIP reauthorization (including (H.R. 3922 and S. 1827) Long-term services and supports Medicare Part D Clinical decision support Opioids and substance use disorder Section 701 of the National Defense Authorization Act for Fiscal Year 2018 (S. 1519)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2017

Q3 Report

In Q3, Anthem, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2017. Original Filing: 300916283.xml

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (reconciliation, individual mandate, cost sharing reduction subsidies) The American Health Care Act and related amendments (H.R. 1628 and H. Res. 154) The Better Care Reconciliation Act of 2017 The Health Care Options for All Act (S. 1201) The Individual Health Insurance Marketplace Improvement Act (S. 1354) The Marketplace Certainty Act (S. 1462) Mental health and substance use (42 CFR Part 2) The Overdose Prevention and Patient Safety Act (H.R. 3545) Individual market and exchange stabilization Association health plans Out of network billing ACA third party payments Telehealth Price of prescription drugs Opioid addiction issues and response (prescription drug monitoring programs)

Agencies Lobbied

Type of Issue

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (reconciliation, individual mandate, cost sharing reduction subsidies) The American Health Care Act and related amendments (H.R. 1628 and H. Res. 154) The Better Care Reconciliation Act of 2017 The Health Care Options for All Act (S. 1201) The Individual Health Insurance Marketplace Improvement Act (S. 1354) The Marketplace Certainty Act (S. 1462) Mental health and substance use (42 CFR Part 2) The Overdose Prevention and Patient Safety Act (H.R. 3545) Individual market and exchange stabilization Association health plans Out of network billing ACA third party payments Telehealth Price of prescription drugs Opioid addiction issues and response (prescription drug monitoring programs)

Agencies Lobbied

Type of Issue

Lobbying Issues

Medicare Advantage (risk adjustment, coding intensity, encounter data, dual-eligible members, reauthorization of special need plans (including H.R. 3168), star ratings, normalization factors) The American Health Care Act and related amendments (H.R. 1628 and H. Res. 154) The Better Care Reconciliation Act of 2017 Creating High-Quality Results and Outcomes Necessary to Improve Chronic Care Act of 2017 (S. 870) The CONNECT for Health Act of 2017 (H.R. 2556, S. 1016) Expanding access to telehealth in Medicare (H.R. 3727) Medicaid managed care Medicaid expansion Medicaid reform (block grants, per capita caps) Medicaid and CHIP reauthorization Long-term services and supports Medicare Part D Clinical decision support Opioids and substance use disorder (including H.R. 3545) Keep Kids Insurance Dependable and Secure Act (S. 1827) Section 701 of the National Defense Authorization Act for Fiscal Year 2018 (S. 1519)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2017

Q2 Report

In Q2, Anthem, Inc. had in-house lobbyists. The report was filed on July 20, 2017. Original Filing: 300896537.xml

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (reconciliation, individual mandate, cost sharing reduction subsidies) The American Health Care Act (H.R. 1628 and H. Res. 154) The Better Care Reconciliation Act of 2017 The Health Care Options for All Act (S. 1201) The Individual Health Insurance Marketplace Improvement Act (S. 1354) The Competitive Health Insurance Reform Act (H.R. 372) Mental health and substance use (42 CFR Part 2) ACA transitional policies Individual market stabilization QHP rate filing process Association health plans Out of network billing ACA third party payments Telehealth Price of prescription drugs Opioid addiction issues and response (prescription drug monitoring programs)

Agencies Lobbied

Type of Issue

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (reconciliation, individual mandate, cost sharing reduction subsidies) The American Health Care Act (H.R. 1628 and H. Res. 154) The Better Care Reconciliation Act of 2017 The Health Care Options for All Act (S. 1201) The Individual Health Insurance Marketplace Improvement Act (S. 1354) The Competitive Health Insurance Reform Act (H.R. 372) Mental health and substance use (42 CFR Part 2) ACA transitional policies Individual market stabilization QHP rate filing process Association health plans Out of network billing ACA third party payments Telehealth Price of prescription drugs Opioid addiction issues and response (prescription drug monitoring programs)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2017

Amendment

Anthem, Inc. amended a lobbying report for in-house lobbying in Q12017 on May 3, 2017 Original Filing: 300879622.xml

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (reconciliation, individual mandate, cost sharing reduction subsidies) ACA transitional policies Proposed HHS Market Stabilization Regulation The American Health Care Act (H.R. 1628 and H. Res. 154) The Small Business Health Fairness Act of 2017 (H.R. 1101) The Competitive Health Insurance Reform Act (H.R. 372) The Protecting Access to Care Act (H.R. 1215) The Self-Insurance Protection Act (H.R. 1304) The Pre-existing Conditions Protection Act of 2017 (H.R. 1121) The Patient Fairness and Relief Act of 2017 (H.R. 633) The Employee Fairness and Relief Act of 2017 (H.R. 661) The Plan Verification and Fairness Act of 2017 (H.R. 706) The State Age Rating Flexibility Act of 2017 (H.R. 708) The Health Coverage State Flexibility Act of 2017 (H.R. 710) The Lower Drug Costs through Competition Act (H.R. 749) Out of network Billing ACA third party payments Telehealth Price of prescription drugs

Agencies Lobbied

Type of Issue

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (reconciliation, individual mandate, cost sharing reduction subsidies) ACA transitional policies Proposed HHS Market Stabilization Regulation The American Health Care Act (H.R. 1628 and H. Res. 154) The Small Business Health Fairness Act of 2017 (H.R. 1101) The Competitive Health Insurance Reform Act (H.R. 372) The Protecting Access to Care Act (H.R. 1215) The Self-Insurance Protection Act (H.R. 1304) The Pre-existing Conditions Protection Act of 2017 (H.R. 1121) The Patient Fairness and Relief Act of 2017 (H.R. 633) The Employee Fairness and Relief Act of 2017 (H.R. 661) The Plan Verification and Fairness Act of 2017 (H.R. 706) The State Age Rating Flexibility Act of 2017 (H.R. 708) The Health Coverage State Flexibility Act of 2017 (H.R. 710) The Lower Drug Costs through Competition Act (H.R. 749) Out of network Billing ACA third party payments Telehealth Price of prescription drugs

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2017

Q1 Report

In Q1, Anthem, Inc. had in-house lobbyists. The report was filed on April 20, 2017. Original Filing: 300876235.xml

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (reconciliation, individual mandate, cost sharing reduction subsidies) ACA transitional policies Proposed HHS Market Stabilization Regulation The American Health Care Act (H.R. 1628 and H. Res. 154) The Small Business Health Fairness Act of 2017 (H.R. 1101) The Competitive Health Insurance Reform Act (H.R. 372) The Protecting Access to Care Act (H.R. 1215) The Self-Insurance Protection Act (H.R. 1304) The Pre-existing Conditions Protection Act of 2017 (H.R. 1121) The Patient Fairness and Relief Act of 2017 (H.R. 633) The Employee Fairness and Relief Act of 2017 (H.R. 661) The Plan Verification and Fairness Act of 2017 (H.R. 706) The State Age Rating Flexibility Act of 2017 (H.R. 708) The Health Coverage State Flexibility Act of 2017 (H.R. 710) The Lower Drug Costs through Competition Act (H.R. 749) Out of network Billing ACA third party payments Telehealth Price of prescription drugs

Agencies Lobbied

Type of Issue

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment) ACA reform (reconciliation, individual mandate, cost sharing reduction subsidies) ACA transitional policies Proposed HHS Market Stabilization Regulation The American Health Care Act (H.R. 1628 and H. Res. 154) The Small Business Health Fairness Act of 2017 (H.R. 1101) The Competitive Health Insurance Reform Act (H.R. 372) The Protecting Access to Care Act (H.R. 1215) The Self-Insurance Protection Act (H.R. 1304) The Pre-existing Conditions Protection Act of 2017 (H.R. 1121) The Patient Fairness and Relief Act of 2017 (H.R. 633) The Employee Fairness and Relief Act of 2017 (H.R. 661) The Plan Verification and Fairness Act of 2017 (H.R. 706) The State Age Rating Flexibility Act of 2017 (H.R. 708) The Health Coverage State Flexibility Act of 2017 (H.R. 710) The Lower Drug Costs through Competition Act (H.R. 749) Out of network Billing ACA third party payments Telehealth Price of prescription drugs

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2016

Q4 Report

In Q4, Anthem, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2017. Original Filing: 300853584.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2016

Q3 Report

In Q3, Anthem, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2016. Original Filing: 300838335.xml

Lobbying Issues

ACA implementation (exchange operations and functionality, risk mitigation programs, CO-OP solvency, risk corridors, risk adjustment) Reinsurance (Taxpayers Before Insurers Act, S. 2803 and H.R. 5904) Age rating bands in the individual health insurance market (H.R. 5921) ACA Special Enrollment Period verification (H.R. 5589) ACA third party payments (H.R. 3742) ACA grace periods (H.R. 5410) ACA Notice of Benefit and Payment Parameters regulations Mental Health and Substance Use (H.R. 2646 and H.R. 4276) Federal Mental Health and Substance Use Disorder Task Force Health Reimbursement Arrangements (H.R. 5447) Comprehensive Addiction and Recovery Act (H.R. 953) Fraud, waste, and abuse Telehealth (S. 2484 and H.R. 4442) Price of prescription drugs Military health care (S. 2943 and H.R. 4909)

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2016

Q2 Report

In Q2, Anthem, Inc. had in-house lobbyists. The report was filed on July 20, 2016. Original Filing: 300818207.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2016

Amendment

Anthem, Inc. amended a lobbying report for in-house lobbying in Q12016 on May 5, 2016 Original Filing: 300804850.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2016

Q1 Report

In Q1, Anthem, Inc. had in-house lobbyists. The report was filed on April 20, 2016. Original Filing: 300802330.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2015

Amendment

Anthem, Inc. amended a lobbying report for in-house lobbying in Q42015 on March 21, 2016 Original Filing: 300787660.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2015

Q4 Report

In Q4, Anthem, Inc. had in-house lobbyists. The report was filed on Jan. 19, 2016. Original Filing: 300776982.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2015

Amendment

Anthem, Inc. amended a lobbying report for representation of WellPoint, Inc. in Q32015 on Jan. 13, 2016. Original Filing: 300771136.xml

Lobbying Issues

General Issues related to the Patient Protection and Affordable Care Act (PPACA), including: Implementation, essential health benefits, exchanges, medical loss ratio, repeal of the health insurer tax, rate review, rate development, enrollment and re-enrollment, plan benefit design, grandfathering, Medicare, discontinuation of health plans, commercial small group size, ACA risk mitigation provisions, the 21st Century Cures Act, risk corridors and excise tax on health coverage. General Issues include: Medicare Advantage; ICD-10; Telehealth Reform; TRICARE 2017; health care costs. Specific Bills include: ACA Small Group definition (H.R. 1624 and S. 1099), Health Information Technology (S.1101 and H.R. 2396), Medicaid reimbursement (H.R. 546 - ACE Kids Act), Fraud and Abuse Prevention (H.R. 1021, H.R. 2298 and S. 1431), Medicare Advantage - Risk Adjustment, Medicare Advantage - Star Ratings, ACA Health Insurance Tax (H.R. 928 and S. 183), ACA Excise Tax (H.R. 2050, H.R. 879, S. 2045) and Telehealth

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2015

Q3 Report

In Q3, Anthem, Inc. lobbied for WellPoint, Inc.. The report was filed on Oct. 20, 2015. Original Filing: 300764019.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2015

Q2 Report

In Q2, Anthem, Inc. (formerly known as WellPoint, Inc.) lobbied for WellPoint, Inc.. The report was filed on July 20, 2015. Original Filing: 300746050.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2015

Q1 Report

In Q1, Anthem, Inc. (formerly known as WellPoint, Inc.) lobbied for WellPoint, Inc.. The report was filed on April 20, 2015. Original Filing: 300724871.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2014

Q4 Report

In Q4, Anthem, Inc. (formerly known as WellPoint, Inc.) lobbied for WellPoint, Inc.. The report was filed on Jan. 20, 2015. Original Filing: 300705080.xml

Lobbying Issues

General Issues related to the Patient Protection and Affordable Care Act (PPACA), including: Implementation, essential health benefits, exchanges, medical loss ratio, insurer tax, rate review, rate development, enrollment and re-enrollment, plan benefit design, grandfathering, Medicare, discontinuation of health plans, ACA risk mitigation provisions, and Military health programs. General Issues include: H.R. 3750 (Telehealth Modernization Act); H.R. 3367 (two-year repeal of ACA Health Insurer Fee); H.R. 4414 (Expatriate Health Coverage Clarification Act of 2014); Medicare Advantage; ICD-10; Telehealth Reform; TRICARE 2017. Specific Bills include: Specific Bills include: H.R. 3367; H.R. 763; S. 603; S.2214; H.R. 3489; H.R. 3541; H.R. 3812; H.R. 3750; H.R. 3077; S. 1787 and, H.R. 3306.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2014

Amendment

WellPoint, Inc. amended a lobbying report for in-house lobbying in Q32014 on March 31, 2015 Original Filing: 300712111.xml

Lobbying Issues

General Issues related to the Patient Protection and Affordable Care Act (PPACA), including: Implementation, essential health benefits, exchanges, medical loss ratio, insurer tax, rate review, rate development, enrollment and re-enrollment, plan benefit design,grandfathering, Medicare, discontinuation of health plans, ACA risk mitigation provisions, and Military health programs. General Issues: Quality and care coordination, innovation, affordability, ICD-10, consumer engagement, utilization trends, payment reform, fraud and abuse prevention, cost-sharing, wellness, advanced imaging management, telehealth, sustainable growth rate, Watson, payment reconciliation and high cost drugs. Specific Bills include: H.R. 3367; H.R. 763; S. 603; S.2214; H.R. 3489; H.R. 3541; H.R. 3812; H.R. 3750; H.R. 3077; S. 1787 and, H.R. 3306

Agencies Lobbied

Type of Issue

Lobbying Issues

General Issues related to the Patient Protection and Affordable Care Act (PPACA), including: Implementation, essential health benefits, exchanges, medical loss ratio, insurer tax, rate review, rate development, enrollment and re-enrollment, plan benefit design, grandfathering, Medicare, discontinuation of health plans, and ACA risk mitigation provisions. General Issues: Quality and care coordination, innovation, affordability, ICD-10, consumer engagement, utilization trends,payment reform, fraud and abuse prevention, cost-sharing, wellness, advanced imaging management, telehealth, sustainable growth rate, Watson, payment reconciliation and high cost drugs. Specific Bills include: H.R. 3367; H.R. 763; S. 603; S.2214; H.R. 3489; H.R. 3541; H.R. 3812; H.R. 3750; H.R. 3077; S. 1787 and, H.R. 3306

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2014

Amendment

WellPoint, Inc. amended a lobbying report for in-house lobbying in Q32014 on Jan. 20, 2015 Original Filing: 300706844.xml

Lobbying Issues

General Issues related to the Patient Protection and Affordable Care Act (PPACA), including: Implementation, essential health benefits, exchanges, medical loss ratio, insurer tax, rate review, rate development, enrollment and re-enrollment, plan benefit design,grandfathering, Medicare, discontinuation of health plans, ACA risk mitigation provisions, and Military health programs. General Issues: Quality and care coordination, innovation, affordability, ICD-10, consumer engagement, utilization trends, payment reform, fraud and abuse prevention, cost-sharing, wellness, advanced imaging management, telehealth, sustainable growth rate, Watson, payment reconciliation and high cost drugs. Specific Bills include: H.R. 3367; H.R. 763; S. 603; S.2214; H.R. 3489; H.R. 3541; H.R. 3812; H.R. 3750; H.R. 3077; S. 1787 and, H.R. 3306

Agencies Lobbied

Type of Issue

Lobbying Issues

General Issues related to the Patient Protection and Affordable Care Act (PPACA), including: Implementation, essential health benefits, exchanges, medical loss ratio, insurer tax, rate review, rate development, enrollment and re-enrollment, plan benefit design, grandfathering, Medicare, discontinuation of health plans, and ACA risk mitigation provisions. General Issues: Quality and care coordination, innovation, affordability, ICD-10, consumer engagement, utilization trends,payment reform, fraud and abuse prevention, cost-sharing, wellness, advanced imaging management, telehealth, sustainable growth rate, Watson, payment reconciliation and high cost drugs. Specific Bills include: H.R. 3367; H.R. 763; S. 603; S.2214; H.R. 3489; H.R. 3541; H.R. 3812; H.R. 3750; H.R. 3077; S. 1787 and, H.R. 3306

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2014

Q3 Report

In Q3, WellPoint, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2014. Original Filing: 300687805.xml

Lobbying Issues

General Issues related to the Patient Protection and Affordable Care Act (PPACA), including: Implementation, essential health benefits, exchanges, medical loss ratio, insurer tax, rate review, rate development, enrollment and re-enrollment, plan benefit design, grandfathering, Medicare, discontinuation of health plans, ACA risk mitigation provisions, and Military health programs.General Issues: Quality and care coordination, innovation, affordability, ICD-10, consumer engagement, utilization trends, payment reform, fraud and abuse prevention, cost-sharing, wellness, advanced imaging management, telehealth, sustainable growth rate, Watson, payment reconciliation and high cost drugs. Specific Bills include: H.R. 3367; H.R. 763; S. 603; S.2214; H.R. 3489; H.R. 3541; H.R. 3812; H.R. 3750; H.R. 3077; S. 1787 and, H.R. 3306

Agencies Lobbied

Type of Issue

Lobbying Issues

General Issues related to the Patient Protection and Affordable Care Act (PPACA), including: Implementation, essential health benefits, exchanges, medical loss ratio, insurer tax, rate review, rate development, enrollment and re-enrollment, plan benefit design, grandfathering, Medicare, discontinuation of health plans, and ACA risk mitigation provisions.General Issues: Quality and care coordination, innovation, affordability, ICD-10, consumer engagement, utilization trends, payment reform, fraud and abuse prevention, cost-sharing, wellness, advanced imaging management, telehealth, sustainable growth rate, Watson, payment reconciliation and high cost drugs. Specific Bills include: H.R. 3367; H.R. 763; S. 603; S.2214; H.R. 3489; H.R. 3541; H.R. 3812; H.R. 3750; H.R. 3077; S. 1787 and, H.R. 3306

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2014

Q2 Report

In Q2, WellPoint, Inc. had in-house lobbyists. The report was filed on July 18, 2014. Original Filing: 300662830.xml

Lobbying Issues

General Issues related to the Patient Protection and Affordable Care Act (PPACA), including: Implementation, essential health benefits, exchanges, medical loss ratio, insurer tax, rate review, rate development, enrollment and re-enrollment, plan benefit design, grandfathering, Medicare, discontinuation of health plans, and ACA risk mitigation provisions.General Issues: Quality and care coordination, innovation, affordability, ICD-10, consumer engagement, utilization trends, payment reform, fraud and abuse prevention, cost-sharing, wellness, advanced imaging management, telehealth, sustainable growth rate, Watson, payment reconciliation and high cost drugs. Specific Bills include: H.R. 3367; H.R. 763; S. 603; S.2214; H.R. 3489; H.R. 3541; H.R. 3812; H.R. 3750; H.R. 3077; S. 1787 and, H.R. 3306

Agencies Lobbied

Type of Issue

Lobbying Issues

General Issues related to the Patient Protection and Affordable Care Act (PPACA), including: Implementation, essential health benefits, exchanges, medical loss ratio, insurer tax, rate review, rate development, enrollment and re-enrollment, plan benefit design, grandfathering, Medicare, discontinuation of health plans, and ACA risk mitigation provisions.General Issues: Quality and care coordination, innovation, affordability, ICD-10, consumer engagement, utilization trends, payment reform, fraud and abuse prevention, cost-sharing, wellness, advanced imaging management, telehealth, sustainable growth rate, Watson, payment reconciliation and high cost drugs. Specific Bills include: H.R. 3367; H.R. 763; S. 603; S.2214; H.R. 3489; H.R. 3541; H.R. 3812; H.R. 3750; H.R. 3077; S. 1787 and, H.R. 3306

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2014

Q1 Report

In Q1, WellPoint, Inc. had in-house lobbyists. The report was filed on April 21, 2014. Original Filing: 300646428.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2013

Q4 Report

In Q4, WellPoint, Inc. had in-house lobbyists. The report was filed on Jan. 21, 2014. Original Filing: 300622474.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2013

Amendment

WellPoint, Inc. amended a lobbying report for in-house lobbying in Q32013 on Jan. 21, 2014 Original Filing: 300622466.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2013

Amendment

WellPoint, Inc. amended a lobbying report for in-house lobbying in Q32013 on Oct. 22, 2013 Original Filing: 300607731.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2013

Q3 Report

In Q3, WellPoint, Inc. had in-house lobbyists. The report was filed on Oct. 21, 2013. Original Filing: 300602040.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2013

Q2 Report

In Q2, WellPoint, Inc. had in-house lobbyists. The report was filed on July 22, 2013. Original Filing: 300581244.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2013

Q1 Report

In Q1, WellPoint, Inc. had in-house lobbyists. The report was filed on April 19, 2013. Original Filing: 300556572.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2012

Q4 Report

In Q4, WellPoint, Inc. had in-house lobbyists. The report was filed on Jan. 22, 2013. Original Filing: 300537967.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2012

Q3 Report

In Q3, WellPoint, Inc. had in-house lobbyists. The report was filed on Oct. 19, 2012. Original Filing: 300514982.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2012

Q2 Report

In Q2, WellPoint, Inc. had in-house lobbyists. The report was filed on July 20, 2012. Original Filing: 300494728.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2012

Amendment

WellPoint, Inc. amended a lobbying report for in-house lobbying in Q12012 on Jan. 17, 2013 Original Filing: 300531806.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2012

Q1 Report

In Q1, WellPoint, Inc. had in-house lobbyists. The report was filed on April 20, 2012. Original Filing: 300472286.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2011

Q4 Report

In Q4, WellPoint, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2012. Original Filing: 300447128.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2011

Q3 Report

In Q3, WellPoint, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2011. Original Filing: 300426191.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2011

Q2 Report

In Q2, WellPoint, Inc. had in-house lobbyists. The report was filed on July 20, 2011. Original Filing: 300402189.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2011

Q1 Report

In Q1, WellPoint, Inc. had in-house lobbyists. The report was filed on April 20, 2011. Original Filing: 300377075.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2010

Amendment

WellPoint, Inc. amended a lobbying report for in-house lobbying in Q42010 on May 3, 2011 Original Filing: 300382954.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2010

Q4 Report

In Q4, WellPoint, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2011. Original Filing: 300350479.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2010

Amendment

WellPoint, Inc. amended a lobbying report for in-house lobbying in Q32010 on May 3, 2011 Original Filing: 300382953.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2010

Q3 Report

In Q3, WellPoint, Inc. had in-house lobbyists. The report was filed on Oct. 18, 2010. Original Filing: 300315665.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2010

Amendment

WellPoint, Inc. amended a lobbying report for in-house lobbying in Q22010 on May 3, 2011 Original Filing: 300382952.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2010

Q2 Report

In Q2, WellPoint, Inc. had in-house lobbyists. The report was filed on July 20, 2010. Original Filing: 300296371.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2010

Amendment

WellPoint, Inc. amended a lobbying report for in-house lobbying in Q12010 on May 3, 2011 Original Filing: 300382950.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2010

Q1 Report

In Q1, WellPoint, Inc. had in-house lobbyists. The report was filed on April 20, 2010. Original Filing: 300269562.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2009

Q4 Report

In Q4, WellPoint, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2010. Original Filing: 300244552.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2009

Q3 Report

In Q3, WellPoint, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2009. Original Filing: 300217408.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2009

Q2 Report

In Q2, WellPoint, Inc. had in-house lobbyists. The report was filed on July 20, 2009. Original Filing: 300190403.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2009

Q1 Report

In Q1, WellPoint, Inc. had in-house lobbyists. The report was filed on April 20, 2009. Original Filing: 300159425.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2008

Q4 Report

In Q4, WellPoint, Inc. had in-house lobbyists. The report was filed on Jan. 16, 2009. Original Filing: 300124016.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2008

Q3 Report

In Q3, WellPoint, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2008. Original Filing: 300104020.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2008

Registration

2nd Quarter, 2008

Registration

2nd Quarter, 2008

Q2 Report

In Q2, WellPoint, Inc. had in-house lobbyists. The report was filed on July 21, 2008. Original Filing: 300083174.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2008

Registration

1st Quarter, 2008

Q1 Report

In Q1, WellPoint, Inc. had in-house lobbyists. The report was filed on April 21, 2008. Original Filing: 300050369.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2007

Registration

1st Quarter, 2006

Registration

Source: Clerk of the U.S. House of Representatives and Secretary of the Senate

Legislators

Bills

Statements

Lobbying

Travel

Lobbyists

Disclosures Filed